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chapter 1 
INTRODUCTION 
1 

TOWARDS TREATMENT MODELING IN CANCER CHEMOTHERAPY 
Thirty-five years ago cytostatic drugs were introduced in clinical practice 
[1, 2, 3]. Nowadays, approximately 40 anticancer drugs are available, in many 
cancers survival has been improved and in certain malignancies part of the 
patients may even be cured [3]. Schedules for clinical application of these 
drugs as single agent or in combination chemotherapy, are mainly developed 
empirically in so-called phase I, II and III studies [A]. However, optimal use 
of cytotoxic drugs requires knowledge of their mode of action, pharmacology, 
and toxic side-effects. 
Major developments in tumor biology, drug pharmacology, and cell 
biochemistry enable a more appropriate selection of drugs and a more rational 
therapeutic application [5, 6]. Interaction of both clinical and basic 
disciplines is necessary in order to establish factors influencing the 
dose-response relationship (Fig 1). 
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Fig 1. Schematic diagram of the principal factors which determine the relation 
between drug prescription and clinical response. 
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The pharmacodynamic action depends much on cell type and may be related to the 
cell kinetics of the target cells [7, 8]. These factors modulate the 
therapeutic and toxic response to the various drugs. 
Mathematical models have been developed, including a number of 
pharmacological and cytokinetic variables, to describe the clinical effects 
of a certain drug in relation to dosage and mode of administration [9, 10, 
11, 12, 13]. The models can be used to evaluate the relative importance of the 
various determinants, aiming at the ultimate purpose: adaptation of drugs and 
treatment schedules in individual patients in order to improve treatment 
results. Such a simulation model has to be fed by quantitative data concerning 
all relevant pharmacological and cytokinetic determinants. 
This study describes pharmacokinetic and pharmacodynamic measurements of 
cytosine arabinoside (ara-C, 1-ß-D-arabinofuranosylcytosine) and its effects 
in patients with acute leukemia. With the data obtained, it is possible to 
develop a mathematical model, in order to estimate the value of treatment 
modeling in human acute leukemia. 
CYTOSINE ARABINOSIDE 
Сігпгааі efficaay 
The introduction of cytosine arabinoside (ara-C, 1-ß-D-arabinofuranosyl-
cytosine, cytarabine) in 1963 represented a great advance in the treatment of 
human acute myeloid leukemia [14, 15, 16]. All currently used treatment 
schemes include ara-C. Clinical studies indicate that ara-C in combination 
with other drugs (adriamycine, thioguanine) induces a complete remission in 
60 to 80% of previously untreated patients with acute myeloid leukemia [17, 18, 
19, 20, 21, 22]. 
Ara-C also proved to be effective in acute lymphoblastic leukemia [23, 24] 
although it is mainly used in refractory or relapsed disease [25, 26, 27, 28] 
or for intrathecal therapy in case of meningeal leukemia [29]. 
Metabolism and mode of aetion 
Ara-C is a synthetic stereoisomer of cytidine (Fig 2)[30]. The metabolic 
pathways are represented schematically in Fig 3. In mammals ara-C is deaminated 
by cytidine deaminase to uracil arabinoside (ara-U, 1-ß-D-arabinofuranosyl-
uracil), which has no antitumour properties [31, 32]. This process mainly 
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takes place in the liver [33]. Ara-C is active intracellularly only; it enters 
leukemic cells by a facilitated diffusion mechanism [34] and is phosphorylated 
intracellularly to cytosine arabinoside triphosphate (ara-CTP)[35, 36, 37]. 
Phosphorylation of ara-C is catalysed successively by deoxycytidine kinase, 
deoxycytidylate kinase, and nucleoside diphosphokinase [38, 39, 40]. Little 
is known about the degradation of ara-CTP. Most likely phosphatases are 
involved in this process [41]. Both ara-C and its monophosphate, ara-CMP, can 
be deaminated intracellularly by cytidine deaminase and deoxycytidylate 
deaminase, respectively [42, 43]. 
The mechanism by which ara-C leads to cell kill has not yet been fully 
established. The major effect is still ascribed to inhibition of DNA synthesis 
[44]. Ara-CTP is a competitive inhibitor of the physiological substrate 
deoxycytidine triphosphate for DNA-polymerizing enzymes [45, 46, 47]. Other 
factors mentioned in literature, which may attribute to the cytotoxic effect, 
are: incorporation of ara-CTP into DNA [48, 49], inhibition of RNA polymerase 
[50], and aberrant replication of DNA strands [51] leading to chromosomal 
alterations [52, 53]. 
Cytokinetic aspects 
Since the cytotoxic action of ara-C is related closely to DNA synthesis, 
the drug is regarded as cytocidal specifically for cells in the S-phase of the 
cell cycle [53, 54, 55, 56]. Therefore, the number of cells eliminated by 
ara-C will depend on the cellkinetic properties of the tumor [57, 58, 59]. 
Whether ara-C interferes with cell cycle progression is not clear. Karon et 
al [60] noted a blockade in the transit of S-phase cells into the Go-phase, 
without influencing transition of G,-phase cells into the S-phase. However, 
Bhuyan et al [61] and Tobey [62] reported a progression delay at the G,-S-
boundary in the presence of ara-C. This difference may depend on cell type 
and ara-C concentration. 
After exposure to ara-C (and elimination of damaged S-phase cells), some 
time is required before a new cohort of cells enters the S-phase compartment 
[63, 64]. Temporarily, even a relative increase of cell influx into the 
S-phase may occur [63, 65]. Thus, the number of vulnerable cells is variable 
and the therapeutic effect of successive ara-C injections is influenced by 
their time interval [65, 66, 67]. 
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Fig 4. Diagram of the processes which are involved in the dose-effect 
relationship of ara-C. 
Dose-effeat diagram of ara-C 
Based on the knowledge reviewed in the preceeding paragraphs, the dose-
effect diagram of ara-C can be designed (Fig 4). The relation between 
administration of ara-C and the ara-C concentration at the target cell depends 
on dose, mode of administration, and pharmacokinetics of ara-C; it is mainly 
determined by tissue accumulation and deamination to ara-U. The quantity of 
ara-CTP formed, is conditioned by the enzymatic properties of the cell. The 
inhibitory effect of ara-CTP on the DNA synthesis depends on the affinity of 
ara-CTP for DNA polymerases and on the intracellular pool of deoxycytidine 
triphosphate. Degree and duration of inhibition define whether cells die or 
recover after cessation of the inhibitory effect. The number of cells to be 
killed is also determined by their cellkinetic properties. Restoration of 
proliferation may be due to continuation of DNA synthesis in non-lethally 
damaged cells and to the rate at which new cells enter S-phase. 
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Resistance to ava-C 
Resistance to ara-C therapy can be innate or acquired. Several mechanisms 
for resistance have been proposed, the most convincing being a decreased rate 
of ara-C phosphorylation due to low kinase activity [35, 36, 68]. In human 
tumors sensitivity is associated with ara-CTP formation too [69, 70], but 
factors responsible for acquired resistance never have been elucidated. A high 
ara-C inactivation rate by deaminating enzymes may play a role [71, 72], but 
such a mechanism would rather decrease the exposure time of the cells to ara-C 
than diminish cellular sensitivity [73]. Other cellular factors, which may 
lead to ara-C resistance are increased pools of deoxycytidine triphosphate 
[74, 75] and changes in polymerase affinity [76]. Additional factors possibly 
modulating treatment responsiveness are differences in vascularization, 
perfusion, and proliferation of the tumor [77]. 
In previously untreated patients some pre-treatment testing has been 
performed in order to predict resistance to ara-C. Data about acquired 
resistance in human leukemia are scarse. 
Prediction of ara-C sensitivity 
Several tests have been described in order to predict the drug sensitivity 
in patients with acute leukemia. Some tests are based on the determination of 
enzyme activities in vitro: high kinase activity being associated with better 
response [69, 78, 79], high deaminase activity indicating ara-C resistance 
[72, 79]. However, Smyth et al [80] did not find a correlation of therapy 
outcome with enzyme activities. In other tests the effect of ara-C on the DNA 
synthesis of leukemic cells [81, 82] or on the colony formation [83, 84] is 
measured in vitro. Furthermore, several in vivo tests have been described, 
merely based on the inhibition of the DNA synthesis of leukemic cells after 
ara-C administration [43, 85, 86, 87]. 
The value of in vitro tests is often questioned. The results of in vivo 
testing seem to correlate better with the clinical response, but their 
practical use is limited. Prediction of ara-C sensitivity on the basis of 
in vitro tests may be improved when all relevant factors can be considered 
simultaneously. 
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OUTLINE OF THIS STUDY 
In the following chapters studies are described dealing with different 
aspects of the dose-response diagram of ara-C (Fig 4). The results provide 
guidelines for a more rational use of ara-C in the treatment of acute leukemia. 
The methods and data can be applied in the development of a clinically 
applicable simulation model for prediction of the antileukemic efficacy of 
treatment, and for individual adaption of the treatment schedule. 
A rapid and sensitive method, employing high pressure liquid chromatography 
(HPLC), has been developed for the determination of ara-C and ara-U in plasma 
and other body fluids (chapter 2). 
The pharmacokinetics of ara-C has been studied by means of this assay 
(chapter 3). Different dosages and different modes of administration have 
been compared. 
The concentrations in cerebro spinal fluid have been measured after 
intravenous bolus injections of 500 and 1000 mg/m body surface ara-C, in order 
to determine the potency of ara-C with respect to leukemic cells present in 
the central nervous system (chapter 4). 
Intracellular phosphorylation of ara-C and dephosphorylation of ara-CTP 
in leukemic blasts have been determined in vitro (chapter 5). Intracellular 
metabolism of ara-C in myeloblasts and lymphoblasts is compared; changes 
observed in relapsed patients are reported. 
The effect of ara-C on the DNA synthesis of leukemic cells in vitro has 
been assessed (chapter 6). The results are related to the phosphorylation 
characteristics. Data obtained in myeloblasts and lymphoblasts are compared 
as are data obtained in previously untreated and relapsed patients. 
The relation between ara-C phosphorylation and cell cycle has been studied 
on partially synchronized sub-populations of leukemic cells, obtained by 
means of counterflow centri fugati on (chapter 7). 
For the determination of ara-CTP in leukemic cells during ara-C treatment, 
an HPLC assay has been developed and some preliminary results about the 
intracellular pharmacokinetics of ara-CTP in vivo are given (chapter 8). 
The perturbation of the relative number of proliferating cells, observed 
in 11 patients in vivo after ara-C administration, is reported (chapter 9). 
The antileukemic and toxic effects of daily administered bolus injections 
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of ara-C (200-500 mg/m ) during 7 to 14 days in patients with relapsed or 
refractory acute myeloid leukemia are described (chapter Jö). 
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ABSTRACT 
A method is described for the determination of cytosine arabinoside (ara-C) 
and its metabolite uracil arabinoside (ara-U) in human plasma. The assay is 
based on separation and quantitative identification of ara-C and ara-U peaks, 
obtained by reversed-phase high pressure liquid chromatography of deproteinized 
plasma samples. For ara-C concentrations exceeding 0.2 μΜ and for ara-U 
concentrations exceeding 4 uM, an injection volume of 100 μΐ is sufficient. 
For lower concentrations an injection volume of 500 μΐ is applied. Ara-C is 
detected at 280 nm with a lowest detection limit of 0.008 uM in plasma; ara-U 
is detected at 254 nm with a lowest detection limit varying from 0.04 to 
0.4 μΜ. The variability is attributed to the presence of variable concen­
trations of an unidentified compound which is eluted together with ara-U. 
The variation coefficient of the whole procedure is about 6% for ara-C 
concentrations above 0.02 μΜ and for ara-U concentrations above 0.4 μΜ. For 
lower concentrations the variation coefficient is about 14%. 
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INTRODUCTION 
Pharmacokinetic studies are indispensible for the understanding of the 
pharmacological action of a drug and may provide a rationale for inter-
individual variability in treatment response [1, 2]. Essential in these 
studies is the feasibility to measure concentrations of the drug and its 
metabolites in plasma and other body fluids. The assay used needs to be 
sensitive and should measure preferably both active and inactive metabolites. 
For clinical application, especially for drug-level monitoring in individual 
patients, the assay ought to be rapid and simple. 
Various methods for the determination of cytosine arabinoside (ara-C, 
1-ß-D-arabinofuranosylcytosine) in plasma have been described. Among them are 
an enzymatic assay [3], bioassays [4, 5, 6 ] , radioimmunoassays [7, 8 ] , gas-
chromatography [6, 9 ] , and determination of radioactivity after administration 
of labeled ara-C [10, 11]. These methods are rather insensitive, not suitable 
for routine application, or are unable to measure uracil arabinoside (ara-U, 
1-ß-D-arabinofuranosyluracil), the inactive metabolite of ara-C [12]. 
High pressure liquid chromatography (HPLC) might meet the requirements. 
However, HPLC procedures reported for the determination of ara-C [13, 14, 15, 
16] are of limited interest, since the detection limits are much higher than 
the concentration at which ara-C is still biologically active [17, 18, 19, 20]. 
Therefore, we developed a more sensitive HPLC method for the determination of 
both ara-C and ara-U in plasma. 
MATERIALS AND METHODS 
Chemicals 
Cytidine (Cyd), 5-methylcytidine (5-CH3-Cyd), deoxycytidine (dCyd), 
uridine (Urd), and deoxyuridine (dUrd) have been purchased from Sigma, St. 
Louis, MO, USA. Ara-C has been purchased from Upjohn, Kalamazoo, MI, USA, and 
ara-U from Calbiochem, San Diego, CA, USA. Tetrahydrouridine (THU) has been 
supplied generously by the Drug Synthesis and Biochemistry Branch of the 
National Cancer Institute, Bethesda, MD, USA. All other chemicals have been 
purchased from E. Merck, Darmstadt, GFR. All chemicals are of analytical 
grade. 
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Blood sanple preparation 
Blood samples of 5 ml are collected in heparinized tubes, containing 50 pg 
of tetrahydrouridine to prevent further deamination of ara-C [21]. After cen-
trifugation (10 min, 2000g , 40C) plasma is collected and ultrafiltrated 
through conical ultrafilters (Centriflo F 25, Amicon) by centrifugation 
(30 min, SOOg , 4 C) in order to remove the bulk of the proteins. To eliminate 
the remaining small molecular weight proteins and polypeptides, 1 ml of the 
ultrafiltrate is mixed with 50 μΐ ice-cold 8 M perchloric acid. After 10 min 
incubation at 0 oC, the precipitate is removed by centrifugation (10 min, 
2000 g, 4 0C). To 1 ml of the supernatant 100 μΐ of 4 M di potassium hydrogen 
phosphate is added. The precipitated potassium Perchlorate is removed by cen­
trifugation. 
The term blank plasma is used for plasma samples taken before administration 
of ara-C. 
HPLC equipment 
The HPLC equipment exists of a Pye Uni cam LC 3-XP pump, an injection valve 
(Rheodyne Model 7120) equipped with a 500-μ1 loop, and two reversed-phase 
columns (Nucleosil 10-C-18, 250 χ 4.6 mm I.D., particle size 10 μπι) linked 
together to improve separation (see HPLC procedure). Two UV detectors are used: 
a UV III monitor LDC 1203 with a 10-μ1 flow cell and a fixed wavelength of 280 
nm (ara-C), and a Pye Unicam LC-UV with an 8-μ1 flow cell and a variable 
wavelength set at 254 nm (ara-U). 
HPLC procedure 
Α 500-μ1 sample of deprotei ni zed plasma is injected into the two linked 
reversed-phase columns. Elution is carried out at a constant flow with 0.2 M 
potassium dihydrogen phosphate, adjusted to pH 2.0 with phosphoric acid. 
Helium gas is led through the eluent to prevent development of air bubbles at 
the low pressure side. Detection of ara-C appears to be optimal at 280 nm, 
whereas for detection of ara-U 254 nm is more appropriate (Fig 1). Peak 
heights are used for quantitation of the assay. The 280/254 nm absorption 
ratio is used to detect impurities underlying the peaks of ara-C and ara-U. 
For concentrations of ara-C above 0.2 μΜ and of ara-U above 4 μΜ an injection 
volume of 100 μΐ is used, and separation on a single column proves to result 
in adequate separation. The maximal run-time for the complete separation of a 
500-μ1 sample with the two-column system is 45 min, whereas separation of a 
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Fig 1. UV spectrum of ага-С ( ) and of ara-U ( ) at pH 2.0 
100-μ1 sample with the one-column system can be carried out in 22 min. 
RESULTS 
Sample preparation 
To prevent dilution of the plasma sample, most protein is removed by ultra­
filtration. In this manner, the final elimination of remaining proteins can be 
carried out with a small volume of perchloric acid. This method combines 
proper deproteinization with minimal dilution (1 ml of the injection sample 
equals 0.866 ml plasma). Deproteinization of the plasma sample leads to a 
recovery of ara-C and ara-U of 92 ± 8% (n=20). This loss agrees with the 
reported binding of these compounds to plasma proteins [16, 22]. 
Chromatographic separation 
The chromatogram of a standard mixture of ara-C, Cyd, dCyd, S-CH^-Cyd, 
ara-U, Urd, dUrd, and uric acid shows that ara-C and ara-U are well separated 
from their analogues (Fig 2). In Fig 3 a chromatogram of a blank plasma 
sample, spiked with ara-C (final concentration 0.024 uM) and ara-U (final 
concentration 0.1 μΜ) is shown. 
Chromatograms of blank plasma samples reveal large differences, especially 
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Fig 2. Separation of a standard mixture of ara-C and ara-U and some of their 
analogues by HPLC. Injection volume 500 μΐ, separation on two-column system 
(see Methods), detection at 280 nm. 
l=Cyd, 2=ara-C, 3=dCyd, 4=5-CH3-Cyd, 5=Urd, 6=uric acid, 7=ara-U, 8=dUrd. 
in patients with acute leukemia. In Fig 4 the chromatograms of 3 different 
patients are shown. All plasma samples tested appear to be free of compounds 
interfering with the detection of ara-C, but part of the samples contains a 
substance with the same elution properties as ara-U in this system. The con­
centration of this compound in plasma varies considerably between patients 
(Fig 4) and accounts for the variable detection limit of ara-U in plasma. 
Since the 280/254 nm ratio is different for ara-U and the unknown compound, 
its influence on the determination of ara-U can be eliminated mathematically. 
Calibration curves and aoauraoy 
Calibration curves of ara-C and ara-U are linear overawide range of con­
centrations and pass through the origin (Fig 5). Detection limits in plasma 
are about 0.008 μΜ for ara-C and about 0.4 μΜ for ara-U. The detection limit 
of ara-U is estimated to be 0.04 μΜ when the interfering compound is absent. 
The coefficient of variation for the determination of ara-C plasmaconcentra-
tions, including the deproteinization step, ranges from 14% at the detection 
limit to 6X at higher concentrations. Detailed information about accuracy at 
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Fig 3. Chromatogram of blank plasma of a pat ient , spiked with ara-C (0.024 μΜ) 
and ara-U (1.0 μΜ). In ject ion volume 500 μΐ, separation on two-column system; 
detection at 280 nm, 0.002 a . u . f . s . (Fig 3a) and at 254 nm, 0.05 a . u . f . s . 
(Fig 3b). 
Dotted lines indicate chromatogram without ara-C and ara-U. 
ι 1 г 
20 30 
retention time (min) 
Fig 4. Chromatograms of blank plasma of three patients (a, b and c) with acute 
leukemia. Injection volume 500 μ! ; separation on two-column system, detection 
at 280 nm, 0.002 a.u.f.s. 
Arrows indicate time at which ara-C and ara-U will be eluated from the column. 
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Fig 5. Calibration curves of ara-C and ara-U. 
Figs a and b: one-column system; injection volume 100 ul; detection at 280 nm. 
Figs с and d: two-colmun system; injection volume 500 μΐ; detection at 280 nm, 
0.002 a.u.f.s. (c) and at 254 nm, 0.02 a.u.f.s. (d). 
Dotted lines and error bars indicate ± twice standard deviation. 
N.B. nmol/ml = μΜ. 
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TABLE 1 
COEFFICIENT OF VARIATION IN THE DETERMINATION OF ARA-C AND ARA-U 
Concentration η Coeff icient of var iat ion 
(nM) (%) 
cra-C 
0.4 10 6 
0.08 6 4 
0.02 9 14 
0.008 8 12 
ara-b 
1.5 5 7 
0.4 7 14 
0.2 8 12 
d i f f e r e n t concentrations is given in table 1. 
DISCUSSION 
Treatment results correlate with differences in pharmacokinetics of ara-C 
in patients with acute myeloid leukemia [ 4 , 23, 24]. Monitoring of plasma-
concentrations in individual pat ients, in order to adjust the administered 
dose, requires a rapid and re l iab le method for the determination of ara-C. 
Al l methods described previously exhibi t major disadvantages. Radioimmuno­
assays and bioassays may be disturbed by endogenous nucleosides, which are 
sometimes present in plasma of patients with leukemia in very high concen­
trat ions [ 2 5 ] . Furthermore, application of bioassays is l imited since ara-C is 
often administered in combination with other cytostat ic drugs [26, 27]. Both 
radioimmunoassays and bioassays require ca l ibrat ion curves, which are only 
l inear over a small concentration range, so that appropriate d i lu t ions must be 
made. Therefore, these procedures are time-consuming and laborious, especially 
when only a few samples have to be measured. Gaschromatography combined with 
mass-spectrometry is very sensi t ive, but too complicated to be performed 
rout inely. Chromatographic separation and measurement of rad ioact iv i ty in 
samples af ter administration of radioactively labeled drug is also very 
sensi t ive, but requires special precautions to prevent environmental contamina­
t i o n and has no value f o r routine monitoring. A l l these objections do not hold 
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for HPLC. Although several HPLC procedures for the determination of ara-C are 
available, the method described in this chapter has obvious advantages: 
- no gradient elution is used 
- the detection limit is low 
- both ara-C and ara-U can be determined 
The described method can be used also for the determination of ara-C and 
ara-U in other body fluids such as urine and cerebro-spinal fluid. Then, a 
one-step deproteinization with perchloric acid only will be sufficient. 
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ABSTRACT 
The pharmacokinetics of cytosine arabinoside (ara-C) has been studied at 
2 
increasing dosages, given by bolus injection (up to 1000 mg/m ) or by constant-
2 
rate infusion (up to 3000 mg/m /hr). Plasmaconcentrations of ara-C and its 
metabolite uracil arabinoside (ara-U) have been measured. 
Data obtained during constant-rate infusions reveal a rapid achievement of 
steady-state plasmaconcentrations of ara-C, which increase linearly with the 
infusion rate. Concentrations of ara-U arrive at higher levels and do not 
attain steady-state within б hours. 
After intravenous bolus injection ara-C plasmaconcentrations decline 
steeply, due to distribution in tissue compartments and rapid deamination to 
ara-U, followed by a slower elimination-phase with half-life times ranging 
from 13 to 33 minutes. The high deamination rate of ara-C hampers proper 
analysis of the ara-C plasmaconcentration as a function of time, and 
consequently,the calculation of important pharmacokinetic parameters. 
Plasmaclearances of ara-C range from 2 to 8 1/min., those of ara-U from 
0.1 to 0.8 1/min. The distribution volume of ara-U (and of ara-C) appears to 
be of the same order of magnitude as the total body water volume. It is 
2 
demonstrated that the pharmacokinetics of dosages ara-C of 500 mg/m and more, 
administered by bolus injection, is non-linear, propably due to saturation of 
the deaminating enzymes. 
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INTRODUCTION 
In pharmacokinetics the kinetic behaviour of drugs and their metabolites 
in blood, excretes and tissues of the body are studied [1]. The most important 
kinetic processes are absorption (depending on way of administration), 
distribution (depending on protein binding and tissue accumulation) and 
elimination (depending on metabolism and elimination). The kinetic behaviour 
is generally characterized by time constants, clearances, and distribution 
volumes. Knowledge about these processes may provide insight in the relation-
ship between drug administration and time-elapse of the drug concentration at 
the level of the target cell. Such information may be helpful in a better 
understanding of the individual variations in the pharmacological effect, 
with the ultimate goal to adapt the dosage scheme for individual patients 
[2, 3, 4]. 
The deoxycytidine analogue cytosine arabinoside(ara-C, 1-ß-D-arabino-
furanosylcytosine) is a powerful drug in the treatment of acute myeloid 
leukemia [5, 6, 7]. It is administered mainly intravenously either by bolus 
injection or by continuous infusion [7]. The bioavailability of ara-C after 
oral administration is very low [8]. Most processes underlying the pharmaco-
kinetic behaviour of ara-C are known. 
After intravenous administration, ara-C is rapidly deaminated to uracil 
arabinoside (ara-U, 1-ß-D-arabinofuranosyluracil) which has no cytostatic 
properties [9, 10]. Deamination is catalyzed by cytidine deaminase, present 
in many tissues [11, 12]. Quantitatively, the liver is of major importance. 
Enzymatic deamination is saturated at high ara-C concentrations: the 
Michael is-Menten constant (K ) of ara-C for cytidine deaminase is about 
100 uM [13]. Protein binding of both ara-C and ara-U is less than 15% [10, 11]. 
The compounds are hydrophilic and after intravenous administration a rapid 
equilibration between blood and other tissues is achieved without significant 
accumulation in any tissue [16]. Both ara-C and ara-U are eliminated by the 
kidneys, the only clearance process for ara-U [17, 18]. For ara-C enzymatic 
degradation is much more important. The majority of the dose administered is 
excreted in the urine within 24 hours, mainly as ara-U [18, 19]. 
The number of pharmacokinetic studies on ara-C in man is limited. In the 
3 
very early studies, H-ara-C has been administered and plasma radioactivity 
has been determined after separation of ara-C and ara-U by thin-layer 
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chromatography [17, 18, 19]. In more recent studies, ara-C has been determined 
by bioassays [20, 21] or gaschromatography [22], without determination of 
ara-U. Most of the data have been obtained only after bolus injections of 
2 
about 100 mg/m or during continuous infusions at low infusion rates 
2 (100 mg/m /24 hr). Pharmacokinetic analysis has always been performed by 
fitting the data to a two-compartment open model with first order processes, 
in which administration and elimination are limited to a central compartment 
[23]. 
Nowadays many cytostatics, including ara-C, are administered at high 
dosages [24, 25, 26, 27]. Since deamination of ara-C is a saturable enzymatic 
process, the pharmacokinetics of ara-C will be non-linear at higher dosage. 
Therefore, the present study is directed to the pharmacokinetics of increasing 
dosages ara-C, administered both by bolus injection or by constant rate 
infusion. Ara-C and ara-U are measured in plasma by means of a newly developed 
high pressure liquid chromatographic assay [28, chapter 2]. It is demonstrated 
that saturation of the deaminase activity affects the pharmacokinetics of 
2 
ara-C after bolus injections at dosages of about 500 mg/m and more, whereas 
? 
the pharmacokinetics of constant rate infusions up to 3000 mg/m /hr appears 
to be linear. As will be discussed, pharmacokinetic analysis of plasma-
concentration versus time curves of ara-C is hampered by the high rate of 
deamination of ara-C. 
MATERIALS AND METHODS 
Patients 
All 37 patients studied are suffering from acute leukemia: 28 of acute 
myeloid leukemia and 9 of acute lymphoblastic leukemia. Ages range from 13 to 
68 years. At the time of the study none of the patients have kidney function 
disturbances, or signs of liver disfunction. On the day of blood sampling no 
other cytostatic drugs are given. Other types of drugs, such as antibiotics 
and allopurinol, usually are continued. 
Thirty-one studies (in 26 patients) are performed after intravenous bolus 
2 injections. Different dosages are administered: 100 mg/m body surface (n=7), 
200 mg/m2 (n=3), 350 mg/m2 (n=3), about 500 mg/m2 (n=13) and 1000 mg/m2 (n=5). 
Fifteen studies (in 12 patients) are done during constant rate infusion with 
2 
rates varying from 4 to 3000 mg/m /hr. Infusion times are 1 hour (n=ll) or 
6 hours (n=4). 
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Collection and preparation of samples 
Before intravenous drug administration and at different time intervals 
thereafter, samples of 5 ml blood are obtained by venipuncture from the 
contralateral arm and collected in heparinized tubes, containing 50 ug tetra-
hydrouridine (kindly supplied by the National Cancer Institute, Bethesda, USA) 
to prevent further deamination of ara-C [29]. Samples are placed on ice and 
after centrifugation (10 minutes, 2000 g, 40C) plasma is removed and stored 
at -20 С until assayed. Deprotei nization is achieved by centrifugal ultra­
filtration through Amicon filters (Centriflo F 25) and by additional 
precipitation of residual protein by 8 M perchloric acid as described 
previously [28, chapter 2]. 
Assay of ara-C and ara-U 
Determination of the concentrations ara-C and ara-U is performed by 
reversed-phase high-pressure liquid chromatography as described previously 
[28, chapter 2]. The lowest detectable concentration of ara-C is about 
0.008 μΜ. For ara-U the detection limit is variable due to background 
impurities, and ranges from 0.04 to 0.4 yM. 
Analysis of plasmaaonaentration versus time curves during constant rate infusion 
From the steady-state plasmaconcentration of ara-C, C,. .,„..
 r
», and the 
ss ^ara-L ) 
infusion rate R the plasmaclearance is calculated: 
C 1ara-C = R / Css(ara-C) t 1 ) 
Analysis of plasmaconcentration versus time curves after bolus injection 
Plasmaconcentration curves as function of time can in most cases be fitted 
to a sum of two exponential terms: 
C t = A 1.e"
t / T l
 + A 2 . e "
t / T 2
 (2) 
where A, and A2 are constants with the dimension of concentration, and 
τι and та are time constants. 
Curve fitting is done by a computer program based on nonlinear least square 
regression. 
6D§l¥§li_9f_ËC§:Ç_Çy!Ty§s 
The ara-C plasmaconcentration versus time curves are f i t t e d to equation 2. 
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Fig 1. Simulation of drug concentration in plasma compartment (C^) and 
tissue compartment (C2) as a function of time. 
Fig a represents the pharmacokinetics of ara-C, Fig b that of ara-U. 
Insert: two-compartment open model, used in simulation. 
C,, plasma concentration; C«, tissue concentration. 
The obtained constants A,, A ?, τι and \г can be used to calculate parameters, 
which describe a two-compartment open model [23], as well as to calculate 
model-independent parameters, such as the mean residence time, the clearance 
and the volume of distribution [30]. Since the plasmaconcentration falls more 
than one decade during the first minutes after injection, it is impossible to 
determine experimentally the initial slope of the plasmaconcentration curve 
of ara-C. The constants A, and τι are therefore subject to a considerable 
error. Since A, is about 50 to 150 times higher than A2, proper calculation 
of both compartimentai and empirical parameters is seriously hampered. 
Only the constants of the second term (describing the elimination-phase of 
the curve) can be determined accurately. This second phase of the curve is of 
major importance, since it is related to the tissue concentration as is 
demonstrated in Fig 1. In this study only the constants A„ and хг are used 
for evaluation of the ara-C pharmacokinetics. 
The half-life time of the elimination-phase of ara-C is calculated from τζ: 
T|(ara-C) = 0 · 6 9 3 τ 2 (3) 
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Fig 2. Plasmaconcentration versus time curves of ara-C (!) and ara-U (0) 
during and after a constant rate infusion of ara-C (500 mg/m 2/hr). 
Due to the high rate of deamination of ara-C, plasmaconcentrations of ara-U 
increase rapidly, so that maximal values are found within 15 minutes. Fifteen 
minutes after ara-C injection, the majority of ara-C has been deaminated to 
ara-U. The elimination phase of the ara-U curve is almost exclusively 
determined by renal elimination of ara-U. When ara-U concentrations versus 
time curves are fitted to equation 2, the elimination of ara-U is described 
by the second term: A^.e 'T2. 
The half-life time of ara-U is calculated from τ? according to equation 3. 
Since ara-U represents the majority of the administered drug and since 
distribution of ara-U is very rapidly as compared to elimination, the dis­
tribution volume V can be approximated from the administered dose ara-C and A-: 
V = dose / Al 2 (4) 
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TABLE 1 
PHARMACOKINETIC PARAMETERS FOR ARA-C AND ARA-U IN PLASMA DURING CONTINUOUS INFUSION 
Patient 
11 
32 
36 
30 
31 
33 
34 
35 
34 
35 
36 
37 
6 
7 
38 
Infusion rate 
(mg/m .hr) 
4 
4 
4 
5 
5 
10 
33 
33 
200 
200 
200 
200 
420 
500 
3000 
C
ss(ara-C) 
(uM) 
0.08 
0.06 
0.15 
0.11 
0.08 
0.3O 
0.65 
1.00 
10.0 
6.2 
11.0 
8.6 
15.5 
15.0 
133 
ara-U,60 rain 
(uM) 
. 
. 
-
-
-
-
-
5.5 
32.8 
37.5 
38.4 
28.7 
74.1 
65.6 
396 
CI 
(1/min) 
6.0 
8.3 
3.2 
4.8 
6.3 
4.0 
5.8 
3.9 
2.3 
3.7 
2.1 
3.2 
3.5 
4.4 
2.6 
С
с г
/
а
„ r\· steady-state concentration of ara-C ss \ ara-L¡ 
''ara-U 60 mm' c o n c e n t ' " a t 1 ° r i 0^ ara-U in plasma after 60 minutes infusion 
CI, plasma clearance of ara-C during steady-state 
RESULTS 
Constant rate infusions 
An example of a constant rate infusion of ara-C during about one hour is 
given in Fig 2. Steady-state plasmaconcentrations of ara-C are reached after 
about 30 minutes. Ara-U plasmaconcentration increases linearly during this 
hour. Using 6 hour infusions it appears that ara-U steady-state concentrations 
are not reached within 6 hours. Both steady-state ara-C concentrations and 
the plasmaconcentration of ara-U after 60 minutes infusion increase linearly 
2 
with the infusion rate up to 3000 mg/m /hr (table 1). The plasmaclearances 
of ara-C calculated according to equation 1 range from 2.1 to 8.3 1/min 
(mean 4.3±1.7 1/min). Clearances calculated from the lowest infusion rate 
2 (about 4 mg/m /hr) are subject to greater error, due to the less accurate 
drug administration in case of such small amounts. After 60 minutes infusion 
the ara-U plasmaconcentration is about 4 times the ara-C concentration. 
Bolus injections 
After an intravenous bolus injection the plasmaconcentration curve of ara-C 
shows a rapid biphasic decline (Fig 3). During the initial 5 minutes after 
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Bolus in ject ion 
100 -
10 -
Fig 3. Plasmaconcentration versus time curves of ara-C (·) and ara-U (o) 
after an intravenous bolus injection of ara-C (1000 mg/m2). 
Dotted line ( Δ — Δ ) : summed curve of ara-C and ara-U. 
injection, the plasmaconcentration decreases at least one decade due to 
distribution and elimination. The high elimination of ara-C by deamination 
is reflected in the ara-U plasmaconcentration curve. Maximal ara-U plasma-
concentrations are always found within 15 minutes, usually even within 5 
minutes. Thereafter, ara-U is eliminated by a slow first order process (Fig 3). 
Thirty-one ara-C curves are analysed. In 29 studies ara-U plasmaconcen-
trations are measured as well. Ten of these curves are not suitable for 
analysis of the ara-U elimination-phase, since sampling period was too short 
(about 60 to 80 minutes),so that only 19 ara-U curves could be analysed. 
Data obtained from the ara-C and ara-U curves are given in table 2. 
Half-life times of ara-C range from 11 to 33 minutes (mean 19±5 min) and are 
independent from the dose administered (Fig 4). The constant A 2 (equation 2) 
is not linear with the dose, but is higher than expected at increasing 
dosages (Fig 4). 
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i: 20 
dose aro-C (mg/m ) dose ara-C (mg/m ) 
Fig 4. Effect of increasing dose on the half-life time of ara-C and on the 
intercept of the elimination-phase of ara-C (A 2). Both constants are derived 
from equation 2 (see under Methods). 
The half-life time remains constant (left figure), whereas the intercept of 
the elimination-phase shows a non-linear increase (right figure; dotted line 
indicates a linear increase). 
Half-life times of ara-U are much longer than those of ara-C, ranging from 
33 to 330 minutes (mean 146±67 min). The constant АД increases linearly with 
the dose. The distribution volumes calculated according to equation 4 range 
from 28 to 79 1 (mean 43±12 1). The renal clearance of ara-U (and ara-C) 
ranges from 0.13 to 0.78 1/min (mean 0.26±0.17 1/min). 
DISCUSSION 
Considerations about pharmacokinetic analysis of data obtained after bolus 
injections 
The pharmacokinetics of ara-C is most ideally described in a flow- and 
capacity-limi ted model, in which many physiological variables are incorporated 
[30, 32, 33]. Although these models can describe elegantly the pharmaco­
kinetics of ara-C and ara-U, a plasmaconcentration versus time curve, 
measured in an individual patient, provides not sufficient information for 
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TABLE 2 
PHARMACOKINETIC PARAMETERS FOR ARA-C AND ARA-U IN PLASMA AFTER BOLUS INJECTION 
Dose 
(mg/m2) 
80 
90 
95 
100 
100 
100 
100 
195 
195 
205 
350 
360 
380 
435 
450 
460 
470 
470 
475 
475 
490 
500 
500 
500 
500 
515 
940 
1000 
1000 
1000 
1000 
Ara-C 
A2 
(UM) 
2.4 
1.2 
1.9 
0.7 
2.0 
1.2 
1.5 
3.9 
6.1 
3.8 
2.6 
2.2 
8.2 
19 
8.9 
2.3 
23 
4.4 
14 
46 
9.8 
4.8 
5.2 
16 
19 
27 
43 
26 
49 
41 
43 
curve 
T2 
(min) 
25 
34 
21 
21 
30 
37 
23 
34 
20 
26 
22 
48 
26 
21 
29 
42 
24 
21 
26 
34 
34 
27 
32 
26 
23 
24 
37 
26 
19 
31 
16 
THara-C) 
(min) 
17 
24 
15 
14 
21 
26 
16 
24 
14 
18 
15 
33 
18 
14 
20 
29 
17 
14 
18 
24 
24 
19 
22 
18 
16 
17 
26 
18 
13 
22 
11 
Ara-U 
A¿ 
(μΜ) 
18 
10 
35 
74 
55 
74 
104 
89 
105 
66 
100 
77 
75 
93 
197 
172 
167 
216 
curve 
T 2 
(min) 
56 
476 
189 
47 
222 
238 
91 
217 
256 
233 
204 
278 
313 
222 
152 
192 
233 
185 
THara-U) 
(min) 
38 
330 
131 
33 
154 
165 
63 
151 
178 
161 
141 
193 
217 
154 
105 
133 
161 
128 
V 
(1) 
34 
79 
37 
37 
54 
56 
37 
28 
31 
49 
41 
48 
48 
42 
31 
43 
41 
32 
TBU 
(1) 
44 
45 
47 
45 
36 
26 
55 
41 
39 
33 
41 
39 
32 
45 
47 
23 
36 
38 
48 
44 
29 
38 
33 
41 
29 
39 
31 
39 
30 
26 
30 
C1
r 
(I/min) 
0.61 
0.17 
0.20 
0.78 
0.24 
0.24 
0.41 
0.13 
0.12 
0.21 
0.20 
0.17 
0.15 
0.19 
0.20 
0.22 
0.18 
0.17 
Aj, τ 2 and Ti/ a r a_(n, constants of the second term of the function which fits in with the data points 
of ara-C; A^, τ'2 and
 T i (
a r a
_ m . similar constants for ara-U 
V, distribution volume calculated from the plasma curve of ara-U (see under Methods) 
TBW, volume of total body water (males. 0.60 χ body weight; females. 0.50 χ body weight, Ref. 31) 
Cl , renal plasma clearance of ara-C and ara-U 
deconvolution of all the variables. 
Pharmacokinetic analysis of the plasmaconcentration versus time curves of 
ara-C after intravenous bolus injections has always been performed by fitting 
the data to a two-exponential function, from which parameters describing a 
two-compartment open model are derived [19, 34, 35]. However, curve-fitting 
to a sum of two exponentials does not imply that the obtained function 
properly describes the proposed model. As is shown in this study, the 
deamination rate of ara-C is very high, resulting in a very steep first phase 
of the plasmaconcentration curve of ara-C. Proper determination of the 
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concentration fall during the initial minutes is technically impossible, 
resulting in inaccurate calculation of the first term of the two-exponential 
function. Consequently, calculated parameters of transfer constants, elimi­
nation constants, and distribution volumes are unreliable. The extreme 
variations and the discrepancies between the pharmacokinetic data reported in 
previous studies [19, 34, 35], as well as the discrepancies observed between 
data, obtained from bolus injections and those obtained from constant rate 
infusions [35], are largely due to this phenomenon. Even calculation of 
model-independent pharmacokinetic parameters is hampered, since the constants 
of the first term (A, and τι) contribute considerably to the calculation of 
mean residence time and area under the curve. A more reliable analysis of 
ara-C plasmaconcentration curves can be obtained in two ways. First of all 
the ara-C plasmaconcentration at zero time can be estimated (for example by 
assuming initial distribution of the administered dose in the total blood 
volume) and used to fit the first phase of the ara-C curve. Secondly, analysis 
of the curve of the summed ara-C and ara-U concentrations may be used. Since 
distribution rates and distribution volume of ara-C and ara-U are essentially 
the same [16, 36], the summed curve is determined by distribution and renal 
elimination only, and can be fitted by a sum of two exponentials. Since the 
rapid process of deamination is skipped, the first term can be determined 
more accurately. The concentration at zero time of the sunrned curve represents 
the ara-C concentration at zero time, and subsequently it can be used for 
analysis of the ara-C curve. 
Constant rate infusions 
The difficulties encountered with the analysis of bolus injections do not 
disturb the analysis of constant rate infusions. 
Data obtained during constant rate infusions reveal a rapid achievement of 
steady-state ara-C concentrations, which increase linearly up to infusion 
2 
rates of about 3000 mg/m . Plasmaclearances of ara-C range from 2.1 to 8.3 
1/min and are comparable to previously reported clearances as calculated 
from constant rate infusion too [35]. 
2 
Concentrations accomplished with the convential infusion rate of 100 mg/m 
during 24 hours are about 0.1 μΜ. This concentration will induce 50% 
inhibition of the DNA synthesis of leukemic cells in the majority of patients 
(see chapter 6). In order to reach 90% inhibition a concentration of about 
2 
1 yM is necessary, corresponding with an infusion rate of about 50 mg/m /hr. 
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Variations in both plasmaconcentration and sensitivity of the leukemic cells 
are considerable and urge to individualization based on actual measurements 
of the parameters. 
Since saturation of phosphorylating enzymes occurs at concentrations over 
2 
10 yM ara-C (see chapter 5) infusion rates exceeding 200 mg/m /hr are only of 
limited value. 
Bolus injections 
The renal clearance of ara-U (and ara-C) is low: 0.13 to 0.78 1/min. The 
plasmaclearance of ara-C (2-8 1/min) represents both renal elimination and 
deamination. Hence, ara-C is mainly eliminated by deamination. 
The distribution volume of ara-U can be estimated from the ara-U plasma-
concentration curve. Since the elimination rate of ara-U is low and the 
tissue-blood ratios approximate a factor one [16], this volume represents the 
real distribution volume. As expected, the calculated volumes are of the same 
order of magnitude as those of the total body water (table 2). 
Metabolic elimination is of major importance for the pharmacokinetics of 
ara-C. Although only the second term of equation 2 is accessible for 
calculation, some interesting aspects of this process are observed. During the 
elimination-phase, ara-C plasmaconcentrations remain far below the Michaelis-
Menten constant (K = 100 μΜ for ara-C), so that saturation of the deamination 
will not occur. This is confirmed by the non-changing half-life times of ara-C 
with increasing dose. However, initial ara-C plasmaconcentrations (i.e. 
immediately after injection) exceed by far the К -concentration. Assuming the 
total blood volume as the initial distribution volume, plasmaconcentrations 
2 
at zero time will range from about 180 μΜ (for 100 mg/m injections) to about 
2 
1800 uM (for 1000 mg/m injections). The higher the dose administered, the 
longer deamination will be saturated, resulting in a longer residence time 
of unmetabolized ara-C and increased tissue availability. Since ara-C tissue 
concentrations are related to A- of equation 2, non-linearity of elimination 
of ara-C during the distribution-phase will be reflected in this constant. 
Only the pharmacokinetics of dosages of 500 mg/m and more are affected 
markedly. 
The area under the curve of the tissue concentration is therapeutically an 
important parameter. This area is determined by the amount distributed over 
the tissues (reflected in Ap), and by the half-life time (reflected in xz)· 
Both parameters are related to the deamination rate. This may provide an 
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explanation of the observation of van Prooi jen et al [34] that the therapeutic 
effect of ara-C is related to the half-life time of ara-C. However, it should 
be realized that the relation between tissue concentration and effect depends 
additionally on the metabolic and cytokinetic properties of the target cells 
[2, 3]. 
The existence of a third slope of the ara-C plasmaconcentration versus time 
curve as reported sometimes [35], is slightly indicated in curves obtained 
after injections of 1000 mg/m beyond 2 hours after administration. This 
phase may represent redistribution of ara-C from small body-compartments: 
e.g., the central nervous system (see chapter 4) or the dephosphorylation of 
intracellularly entrapped ara-C triphosphate (see chapter 5). However, ara-C 
concentrations are too low for accurate analysis of this phase. 
In conclusion, deamination of ara-C highly affects the tissue pharmaco­
kinetics by inactivating a large fraction of ara-C before steady-state 
distribution is achieved, especially when lower dosages are administered by 
bolus injection. Pharmacokinetically this mode of administration is less 
favourable in comparison to short infusions. Otherwise the high plasma-
concentration immediately after injection may be of great importance to 
accomplish therapeutic concentrations in body compartments, which are 
notorious sanctuaries for leukemic cells (see chapter 4). 
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ABSTRACT 
Prophylaxis and treatment of meningeal leukemia is a big problem in the 
management of acute leukemia. Most cytostatic drugs enter poorly into the 
cerebro-spinal fluid (CSF); therefore, attention has to be paid to their 
delivery to this body compartment. 
To evaluate pharmacokinetic behaviour of cytosine arabinoside (ara-C) in 
the CSF-compartment, ara-C and uracil arabinoside (ara-U) concentrations have 
been measured in plasma and CSF after intravenous bolus injections of 500 and 
1000 mg/m2 ara-C. 
Plasmaconcentrations of ara-C decline rapidly due to extensive deamination 
to its inactive metabolite ara-U. Only a relatively small amount of ara-C is 
transferred to the CSF. Nevertheless, therapeutic concentrations are attained 
shortly after injection. The CSF concentration of ara-C declines rather 
slowly (half-life time of about 100 minutes), due to the absence of deaminase 
activity in CSF. Consequently, intravenous bolus injections of ara-C result in 
cytotoxic concentrations in the central nervous system, which remain long 
enough to be effective against leukemic cells, present in this compartment. 
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INTRODUCTION 
Cytostatic treatment of acute leukemia results in 60 to 80% of the patients 
in an apparent elimination of the leukemic cells present in blood, bone marrow 
and other tissues [1, 2, 3, 4, 5, 6]. Unfortunately, most cytostatic drugs do 
not reach effective concentrations in the central nervous system (CNS)[7]. 
Leukemic cells present in the CNS may therefore escape eradication and 
continue to proliferate, leading to meningeal leukemia. 
In acute lymphoblastic leukemia 30 to 40% of the first complete remissions 
ends as an isolated relapse in the CNS [1, 2, 6, 8, 9] Early prophylactic 
treatment to the CNS, consisting of irradiation of the neuroaxis and/or 
intrathecal administration of cytostatic drugs, has decreased markedly the 
occurrence of meningeal leukemia to less than 15% [1, 2, 3]. 
Acute myeloid leukemia is less frequently complicated by meningeal 
involvement [4, 6, 8, 9, 10, 11]. This is ascribed to the relative short 
duration of the hematologic remission or to different biological properties 
of the leukemic cells. However, there is also a marked difference in the 
cytostatic regimens, used for remission induction therapy. Treatment of acute 
myeloid leukemia is based on cytosine arabinoside (ara-C), combined with 
anthracyclines and other drugs [4, 5, 6], whereas treatment of acute lympho­
blastic leukemia is based on prednisone-vincristine regimens [1, 2, 3]. 
Differences in pharmacokinetic properties of the various drugs with respect 
to the CNS-compartment, may also attribute to the different incidence of 
CNS involvement. 
Information about the concentration of cytostatic drugs within the CNS-
compartment can not be derived from the plasma concentration curve, but can 
only be obtained by direct sampling of the cerebro spinal fluid (CSF)[12]. 
Data about the pharmacokinetics of ara-C in the CNS are scarse. Distribution 
3 
studies in mice with Η-labeled ara-C have shown that the drug is rapidly 
distributed over the body tissues with exception of the CNS [13, 14]. Ho et 
al [15] measured ara-C concentrations in CSF in a patient during constant 
rate infusion: the CSF concentration remained 40% of the ara-C plasma concen­
tration After intrathecal administration, ara-C showed first order elimination 
from the CSF with a half-life time of about 2 hours [15]. Recently, some 
preliminary data are reported about ara-C concentrations accomplished in CSF 
by a one-hour intravenous infusion of 3000 mg/m ara-C. Maximal values ranged 
from 2.6 to 10.6 μΜ in CSF and the half-life times in CSF varied from 50 
45 
to 330 minutes [16]. 
In the present study it is demonstrated that intravenous bolus injections 
of 500 and 1000 mg/m body surface ara-C result in therapeutic ara-C concen-
trations in the CSF. Elimination of ara-C from the CSF-compartment is much 
slower than elimination from the central compartment. This difference can be 
explained by the absence of deaminating activity in the CNS [17]. 
MATERIALS AND METHODS 
Patients, drug administration and sampling 
Measurements are performed in 12 patients*, all being treated for acute 
lymphoblastic leukemia. Ages range from 3 to 46 years, 10 patients are older 
than 13. At the moment of investigation, 6 patients are in complete remission, 
one suffers from an isolated meningeal leukemia. The other 5 patients are 
relapsed hematologically, 4 of them with concomittant meningeal involvement. 
Five patients received cranial irradiation more than 2 months before ara-C 
administration. 
Ara-C is administered to all patients by rapid intravenous injection. 
2 2 
Dosages administered are 500 mg/m body surface (n=10) or 1000 mg/m body 
surface (n=12). No other cytostatic drugs are given simultaneously. 
Samples of CSF are obtained by lumbar puncture, except in one patient who 
has an Ommaya reservoir. The time period between drug administration and CSF 
sampling varies from 15 to 495 minutes. After 3 injections multiple CSF 
samples are obtained. 
Following 15 out of 22 injections, serial plasma samples are taken in order 
to study the plasma pharmacokinetics. 
Sample preparation and Chromatographie assay 
All samples are collected in heparinized tubes, containing 50 ug tetra-
hydrouridine (kindly supplied by the National Cancer Institute, Bethesda, USA) 
to prevent further deamination after sampling [18]. Plasma samples are de-
proteinized by ultrafiltration (Centriflo F 25, Amicon) followed by 
precipitation with 8 M perchloric acid. CSF samples are deproteinized by 
perchloric acid only. Ara-C and ara-U (uracil arabinosine) concentrations are 
* Three patients are treated at the Department of Pediatrics (head: prof. dr. 
E.D.A.M. Schretlen), University Hospital, Nijmegen. 
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measured by reversed-phase liquid chromatography. Sample preparation and 
chromatographic procedure are described in detail in chapter 2. 
Pharmacokinetic analysis of data 
Plasmaconcentration versus time curves of ara-C are fitted to a two-
exponential function: C. = Α,ε 1 + A^e 'T2. The second term describes the 
elimination phase. Only the half-life time of this phase, ТЛага-С), 
calculated from іг is used to compare the elimination of ara-C from the total 
body compartment and the CSF compartment. A ? represents the intercept of the 
elimination phase. (For more details: see chapter 3). 
In most patients only one CSF sample is obtained, so that calculation of 
individual pharmacokinetic parameters about half-life time of ara-C in the 
CSF is not possible. From the combined individual measurements the half-life 
time of ara-C in the CSF is estimated by fitting these data to a one-
-t/r 
exponential function: Сх,
С5рч = A'e . 
RESULTS 
Plasmaconcentration versus time curves 
Examples of plasmaconcentration versus time curves, obtained with each 
dosage, are shown in Fig 1. 
After intravenous bolus administration of ara-C, the ara-C plasma 
concentration falls to less than 5% of the initial value within 15 minutes. 
This steep decline is caused by distribution over the tissues and by deamina-
tion to inactive ara-U. After this so-called distribution phase, ara-C is 
eliminated with a half-life time between 12 and 29 minutes. The ara-C 
concentration during the elimination phase depends also on the intercept of 
the second term: A 9. This parameter shows large variations: ranging from 
? ? 
2.3 to 27 μΜ after 500 mg/m injections and from 41 to 139 μΜ after 1000 mg/m 
injections. 
Maximal ara-U plasmaconcentrations are reached very rapidly, and range 
from 70 to 110 μΜ (after 500 mg/m ) and from 150 to 260 μΜ (after 1000 mg/m 2). 
With higher dosage maximal values are reached later on due to saturation of 
the deaminating activity during the initial minutes after injection (see also 
chapter 3). Elimination of ara-U is relatively slow; half-life times range 
from 105 to 280 minutes. 
Pharmacokinetic parameters of individual patients are given in table 1. 
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Fig 1. Plasmaconcentration versus time curves of ara-C and ara-U after intra­
venous bolus injections of 500 mg/m 2 (Fig la) and of 1000 mg/m2 (Fng lb). 
Different symbols represent different patients. 
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Fig 2. Ara-C (·) and ara-U (о) concentrations in cerebro spinal fluid as a 
function of time after intravenous bolus injections of 500 mg/m 2 (Fig 2a) and 
of 1000 mg/m2 (Fig 2b). 
Speckled area, range of ara-C plasmaconcentrations; lined area, range of 
ara-U plasmaconcentrations. Data belonging to one injection are connected. 
48 
TABLE 1 
PHARMACOKINETIC PARAMETERS FOR ARA-C AND ARA-U IN PLASMA AND CEREBRO-SPINAL FLUID 
AFTER BOLUS INJECTION 
Dosage ara-C T J ( a r a 4 j p ) A2 Ts(ara-U)pl Cmax(ara-U)pl THara-C)CSF 
2 
(mg/m ) (min) (uM) (min) (uM) (mm) 
¡00 24 
18 
12 
29 
19 
17 
14 
17 
18 
13 
mean t s.a. lö.l ± o.ì 
)00 26 
22 
13 
15 
28 
mean ± s.d. 23. tí t С. 6 
10 
14 
26 
2.3 
4.8 
23 
19 
27 
16 
26 
17 t 
43 
41 
139 
119 
85 
ob t 
9 
4 4 
172 
141 
272 
151 
217 
178 
165 
223 
154 
138 
loi t 
105 
280 
120 
125 
156 
1Ь7 ± 
tS 
71 
110 
90 
80 
85 
75 
85 
70 
80 
80 
105 
8C ± 13 
150 
170 
240 
230 
260 
HO i •!? 
6ΰ 
^ Н а г а - О п І ' '•a'f-life time of elimination phase of ara-C in plasma 
A^, intercept of elimination phase of ara-C 
T,. ... ., h a l f - l i f e time of ara-U In plasma 
Snaxíara-lMpl' max1mal plasma concentration of ara-U 
Ti(ara-CKSF· h a l f - l i f e time of ara-C in CSF (cerebro-spinal f lu id ) , calculated from 
pooled measurements of al l patients 
Conoentratione of ara-C and ara-U in cerebro spinal fluid 
Two hours af ter intravenous in ject ion of ara-C, the ara-C concentration 
in CSF exceeds more than 5 times the corresponding plasmaconcentration, and 
ranges from 0.8 to 2.9 μΜ. Elimination of ara-C from the CSF occurs at a lower 
rate than from the blood. The estimated overall h a l f - l i f e time of ara-C in CSF 
is 66 minutes (500 mg/m ) and 126 minutes (1000 mg/m ). Assuming an extra­
c e l l u l a r volume in the CNS of 400 ml for patients over 13 years of age, the 
t o t a l amount of ara-C transferred to the CSF is calculated. I t represents 
less than 0.1 0/oo of the dose administered. 
Delivery of ara-C to the CSF occurs only during a short time period af ter 
intravenous bolus i n j e c t i o n , since ara-Cis rapidly eliminated from the blood. 
Fifteen minutes a f t e r i n j e c t i o n the ara-C concentration found in CSF is 
already 6 μΜ. The ara-C concentration in CSF exceeds the plasmaconcentration 
af ter about 60 minutes. 
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The ara-U concentration in CSF remains below the plasmaconcentration for 
5 to 6 hours, confirming the low transfer constant of ara-C and ara-U to the 
CSF reported by Ho et al [ 1 5 ] . 
The ara-C and ara-U concentrations observed in CSF are demonstrated in 
Fig 2. 
DISCUSSION 
Delivery of cytostatic drugs to the CNS is quite different from drug 
distribution to other tissues. The amount of drug transferred to this 
compartment is relatively small. Therefore, information concerning the drug 
concentrations achieved in the CNS can not be derived from analysis of plasma-
concentration curves, but can only be obtained by direct measurements 
The CNS is an apprehended sanctuary of leukemic cells, responsible for a 
considerable part of the relapses in acute lymphoblastic leukemia. Knowledge 
about the pharmacokinetic behaviour of cytostatic drugs with respect to the 
CNS-compartment may lead to development of treatment schemes with better 
prophylactic and therapeutic efficacy against meningeal leukemia. 
Previous studies indicated that intravenous administered ara-C, like many 
other cytostatic drugs, is transferred rather slowly from blood to CSF [13, 
14, 15]. Therefore, it is assumed that long-lasting infusions are necessary 
to accomplish cytostatic concentrations in the CSF. However, the results of 
the present study demonstrate that intravenous bolus injections of 500 and 
1000 mg/m ara-C result in CSF concentrations exceeding 1 μΜ. These ara-C 
concentrations are comparable to plasmaconcentrations during constant rate 
infusions of 50 mg/m per hour, and will produce a pronounced inhibition of 
the DNA synthesis of leukemic cells (see chapter 6). The high plasmaconcen-
2 
tration immediately after injection of 500 - 1000 mg/m produces drug delivery 
to the CSF, which is comparable to the amount delivered during a one-hour 
2 
infusion of 3000 mg/m ara-C [16]. The ara-C concentration in the CSF is well 
sustained, due to the absence of deaminase activity in the CNS [17], in 
contrast to the plasmaconcentration, which declines steeply, due to rapid 
deammation of ara-C to ara-U [12, chapter 3]. The half-life times of ara-C 
in the CSF are considerably longer than in plasma (about 80 minutes versus 
about 19 minutes), and are fairly similar to those reported after high-dose 
infusions [16] and to those after intrathecal administration of ara-C [15]. 
2 
The half-life time calculated from the data of 1000 mg/m injections is longer 
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than calculated from 500 mg/m injections. This difference is probably not 
related to the dose. It is more likely to be due to the presence of more 
patients with overt meningeal leukemia in the higher dosage group. Meningeal 
involvement is known to cause a slower elimination of drugs from the CSF-
compartment [19]. 
It can be concluded that intravenous bolus injections of ara-C accomplish 
CSF concentrations, which are effective against leukemic cells. The low 
incidence of meningeal involvement in patients with acute myeloid leukemia and 
in patients with malignant lymphomas treated with ara-C containing schemes 
[20, 21], may be related to this particular pharmacokinetic property of ara-C. 
Therefore, ara-C seems more suitable in prevention and treatment of meningeal 
involvement by systemic administration than methotrexate, which is currently 
under investigation for this purpose [22, 23, 24]. High-dose methotrexate 
infusions during several hours are necessary to reach therapeutic concentra-
tions in the CSF [23, 24]. This treatment is potentially dangerous [25], so 
that special precautions are necessary [23, 25, 26]. In contrast, bolus 
injections of ara-C are easy to administer and a single injection does not 
produce significant myelosuppression, not even at high dosages [27]. Side-
effects mainly consist of nausea and vomiting during some hours [27, 28, 
chapter 10]. Based on these findings, the use of ara-C in the treatment of 
acute lymphoblastic leukemia should be considered because of its potential 
benefit in prophylaxis and therapy of meningeal leukemia. 
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ABSTRACT 
The cytostatic effect of cytosine arabinoside (ara-C) depends on the intra­
cellular amount of its phosphorylated metabolite cytosine arabinoside tri­
phosphate (ara-CTP). In this study formation and degradation of ara-CTP by 
leukemic cells of 69 patients with acute leukemia have been measured. 
3 
Cells have been incubated in vitro with H-ara-C and the amount of ara-CTP 
formed, has been determined after separation of the nucleotides by thin-layer 
chromatography. 
Ara-C phosphorylation appears to be a saturable process. The К -equivalents 
vary between 1.1 and 16.2 μΜ ara-C. Maximal ara-CTP formation ranges from 12 
to 125 pmol ara-CTP/10 cells in 30 minutes. The phosphorylation activity does 
not correlate with the percentage of proliferating cells. 
Data obtained with myeloblasts and lymphoblasts are comparable. In 
previously untreated patients with acute myeloid leukemia, higher phospho­
rylation seems to be associated with more favourable therapeutic effect. 
Although relapsed leukemia is less sensitive to ara-C, the ara-CTP formation 
in these patients appears to be increased. 
The intracellular half-life time of ara-CTP measured in vitro ranges from 
53 to 210 minutes. Ara-CTP levels are maintained longer in lymphoblasts 
than in myeloblasts. 
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INTRODUCTION 
Cytosine arabinoside (ara-C, 1-ß-D-arabinofuranosylcytosine) is a synthetic 
analogue of deoxycytidine, used mainly in the treatment of acute myeloid 
leukemia [ 1 , 2 ] . After administration, ara-C is deaminated rapidly to uraci l 
arabinoside (ara-U, 1-ß-D-arabinofuranosylcytosine), which has no cytostat ic 
properties [ 3 ] . Ara-C i t s e l f is not active but i t must be phosphorylated 
in t race l lu la r l y to ara-C triphosphate (ara-CTP), which inh ib i ts the DNA 
synthesis [4 , 5 ] . The ara-C concentration at the target cel l at various time 
intervals af ter drug administration depends on dosage, mode of administration 
and rates of d is t r ibu t ion and deamination [ 6 , 7 ] . The amount of ara-CTP 
accumulated i n t race l l u l a r l y is the resultant of the ara-C concentration at the 
target c e l l , ce l l membrane transport, i n t race l l u la r phosphorylation rate to 
ara-CTP, and inact ivat ion rate of ara-CTP by dephosphorylation. The amount of 
in t race l lu la r ara-CTP is essential ly the major determinant in the cytostat ic 
eff icacy of ara-C [8 , 9, 10, 11]. 
Ara-C enters the ce l l very rapidly by f a c i l i t a t e d d i f fus ion [12, 13]. 
Within 1 minute in t race l lu la r concentration equals the ext racel lu lar concen-
t ra t ion [14, 15, 16, 17]. In t race l lu la r ly ara-C is converted to ara-C mono-
phosphate (ara-CMP) by deoxycytidine kinase [ 8 , 13]. This enzymatic step is 
ra te - l im i t ing in the formation of ara-CTP [14, 17]. The natural substrate for 
th is enzyme is deoxycytidine, which has a higher a f f i n i t y for the enzyme than 
ara-C (K^ of deoxycytidine: 2.5 - 14 pM, Km of ara-C: 15 - 40 цМ)[14, 18, 19]. 
Feed-back i n h i b i t i o n of deoxycytidine kinase occurs by deoxycytidine t r i ­
phosphate [18, 19, 2 0 ] , whereas ara-CTP exerts l i t t l e feed-back i n h i b i t i o n 
[ 2 1 ] . Therefore, conversion of ara-C to ara-CMP is affected markedly by the 
i n t r a c e l l u l a r pools of deoxycytidine and deoxycytidine triphosphate [18, 19, 
20]. Deoxycytidine kinase a c t i v i t y has been measured in a variety of normal 
and neoplastic t issues, both in animals and man [20, 22, 23, 24]. I t s a c t i v i t y 
in human leukemic c e l l s shows wide variations [24, 25, 26, 27]. Phosphoralation 
of ara-CMP to ara-C diphosphate (ara-CDP) and ara-CTP is catalyzed by deoxy-
cyt idy late kinase and nucleoside diphosphokinase, respectively [28, 2 9 ] , the 
characterist ics of these enzymes with respect to ara-C phosphorylation have 
been studied less extensively [ 3 0 ] . 
I t is often postulated that phosphorylation of ara-C is influenced by the 
i n t r a c e l l u l a r a c t i v i t y of deaminating enzymes [27, 3 1 , 32, 33, 34]. However, 
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recent data [35] demonstrate that the intracellular deammafing enzymes lower 
the extracellular ara-C concentration without reducing the deoxycytidine 
kinase activity. 
The pathways by which ara-CTP is dephosphorylated are not very well defined. 
Nucleoside tri- and diphosphatases are assumed to be involved in the con-
version of ara-CTP to ara-CMP. The conversion of ara-CMP to ara-C (by 5'-
nucleotidase) or to ara-UMP (by deoxycytidylate deaminase) will be rate-
limiting [19, 36]. 
The accumulation of ara-CTP in intact leukemic cells has been measured by 
several investigators [15, 33, 37, 38, 39], showing wide variations between 
individual patients. The relation between the observed differences and the 
variations in clinical efficacy of ara-C has as yet not been established. 
Some in vitro data about the retention of ara-CTP within leukemic cells have 
been reported by Rustum et al [38], the elimination of ara-CTP from leukemic 
cells appeared to be a very variable process and a correlation between ara-CTP 
retention and duration of complete remission was observed. 
In this chapter data are reported of in vitro measurements of both 
phosphorylation of ara-C and dephosphorylation of ara-CTP in leukemic bone 
marrow cells of patients with acute myeloid and acute lymphoblastic leukemia. 
In vitro phosphorylation and the effect of remission induction therapy are 
compared in patients with untreated acute myeloid leukemia. Changes observed 
in the cellular metabolism of ara-C in patients with relapsed acute myeloid 
leukemia are reported. 
MATERIALS AND METHODS 
Patbents 
Intracellular metabolism of ara-C is studied in vitro in 51 patients with 
acute myeloid leukemia (AML) and in 18 patients with acute lymphoblastic 
leukemia (ALL) at diagnosis and/or at subsequent relapse. First line therapy 
of ALL does not include ara-C: neither in the remission induction regimen nor 
in the maintenance treatment during first complete remission. Patients with 
AML are initially treated according to the EORTC treatment protocol LAM 5. 
2 2 
adriamycin 50 mg/m body surface i .v. on day 1, v incr is t ine 1.0 mg/m i . v . on 
? day 2, ara-C 80 mg/m i . v . once every 12 hours on day 3 - 8 . Treatment results 
of the f i r s t remission induction course are evaluated as fol lows. 
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0. Not évaluable (NE): patients who died before therapy could be evaluated; 
1. Complete remission (CR): patients with complete disappearence of leukemic 
α 
cells from the peripheral blood and recovery of granulocytes (>1.0xl0 /1) 
9 
and thrombocytes (>100xl0 /1), with less than 5% blast cells in a normo-
cellular bone marrow; 
2. Partial remission (PR): patients with a marked reduction (>50S) of leukemic 
cells in the bone marrow, combined with a recovery of the peripheral 
blood as defined under complete remission; 
3. Response (R): patients with a reduction of leukemic cells in the bone 
marrow but only partial improvement of peripheral blood counts; 
4. Failure (F): patients without improvement of peripheral blood and bone 
marrow. 
ßowj- lo j 
Studies are performed in leukemic bone marrow cells, usually obtained by 
aspiration from the sternum. In part of the patients leukemic cells from 
both bone marrow and peripheral blood are studied. 
Blood and bone marrow samples are collected in buffered acid citrate 
dextrose solution (ACD formula A, pH 7.4). The admixture of peripheral 
nucleated cells in the bone marrow samples is calculated by the method 
described by Holdrinet et al [40]. Only samples containing less than 25% 
peripheral blood admixture and more than 60% leukemic cells are used for 
further evaluation. The cells are washed once in ACD in order to prevent 
fibrin formation during incubation. Samples are diluted in medium 199 (Flow 
Laboratories) buffered with 10 mM Tris (pH 7.4 at 37 С) and supplemented by 
10% heat-inactivated fetal calf serum (Flow Laboratories) to a final cell 
concentration of 1-2 xlO nucleated cells per ml. Of all samples the 
percentage cells in the S-phase of the cell cycle is determined by flow-
cytometry, after staining of the nuclei with a hypotonic ethidium bromide 
solution [41](for details see chapter 8). 
Determination of uptake and phosphorylation of ara-C 
Aliquots of the cell suspension are incubated in triplicate during 30 min 
at 37 С with 2 pCi H-ara-C (Radiochemical Centre Amersham, specific activity 
28 Ci/mmol) and varying amounts of unlabeled ara-C. The final ara-C concen­
trations range from 0.08 to 41 μΜ. Incubation is stopped by adding 2 ml ice-
cold buffered saline. The cells are washed 4 times to remove excess of ara-C 
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with buffered saline containing 0.5% (w/v) bovine albumine to prevent cell 
loss. The cell pellets are transferred to counting vials, using 1 ml distilled 
water, and then 9 ml Instagel (Packard) is added. The total amount of intra-
cellularly entrapped ara-C of duplicate samples is determined by scintillation 
counting (LKB 81000) and correction for counting efficiency and specific 
activity. The variation coefficient of the determination is 6% (n=26). 
The intracellular radioactivity of the cells of the third aliquot is 
extracted with 500 yl ethanol/water solution (1:1, v/v) of -200C. After 15 
minutes, the precipitated protein is removed by centri fugati on and the super­
natant is used for chromatographic analysis. More than 95% of the intra­
cellular radioactivity is extracted. 
Determination of the dephosphorylatioK of ara-CTP 
After incubation during 30 minutes at 370C with 5 yd' H-ara-C (specific 
activity 28 Ci/mmol) and subsequent removal of the extracellular ara-C by 
washing the cells 4 times with buffered saline, the cell pellet is resuspended 
in fresh drug-free medium and incubated again at 37 С After 30, 60, 90 and 
120 minutes of re-incubation, the cells are collected by centrifugation 
(4 min, 1000 g, 4 0C). The total amount of radioactivity delivered to the 
incubation medium is counted and chromatographic separation is performed to 
characterize the radioactive products in the medium. The intracellular 
retention of radioactivity is measured and the percentage of radioactivity, 
present as ara-CTP, is determined after chromatography. 
Identification o f the radioactive compounds by thin-layer chromatography 
Separation of the nucleotides is performed on PEI-cellulose-F plates 
(E. Merck Ag) by ascending chromatography. Two systems are used: separation 
of the mono-, di-, and triphosphates is achieved in 0.2 M ammonium sulphate, 
whereas separation of ara-CTP and ara-UTP is achieved in a solvent of 0.25 M 
formic acid and 0.25 M lithium chloride [42]. After chromatography, bands of 1 
cm are transferred to counting vials containing 4 ml 1 N hydrochloric acid 
[43]. The amount of radioactivity in each vial is counted after addition of 
6 ml Instagel (Packard) and the relative amount in each peak is calculated 
(Fig 1). Identification of the peaks is performed by simultaneous separation 
of a standard mixture. Radioactivity is recovered quantitatively from the 
plates (recovery 93±10%, n=17). The coefficient of variation of the deter­
mination of ara-CTP is 5% (n=14). 
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Fig 1. Separation of H-labeled mono-, d i - , and triphosphates of ara-C and 
ara-U on PEI-cellulose plates. After development, f ract ions of 1 cm are 
scraped of f from the plates into counting v ia ls in order to determine the 
d i s t r i b u t i o n of the r a d i o a c t i v i t y over the plates. 
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Separation of H-ara-C from i t s metabolite H-ara-U in the culture medium 
after re-incubation is performed on s i l i c a plates F 254 (E. Merck Ag) with 
water-saturated 1-butanol as solvent [ 4 4 ] . Spots of ara-C and ara-U are 
i d e n t i f i e d by the addit ion of non-labeled compounds and v isual izat ion in UV-
l i g h t . Radioactivity in both spots is quant i f ied a f t e r e lut ion in 4 ml water 
and addition of б ml Instagel. 
RESULTS 
Intracellular accumulation of phoophorylated ara-C 
After incubation with ara-C and the subsequent wash procedure, no un-
phosphorylated ara-C is found within the c e l l s . The i n t r a c e l l u l a r accumulation 
of ara-C appears to be l inear during 120 minutes incubation (n=10) with 
d i f f e r e n t concentrations ara-C (0.08 to 10 μΜ). Therefore, a f ixed incubation 
time of 30 minutes is used in a l l experiments. 
At high ara-C concentrations, saturation of i n t r a c e l l u l a r accumulation 
occurs. Hence, i n t r a c e l l u l a r accumulation can be characterized by a 
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Fig 2a. Phosphorylation of ara-C in 30 minutes at different ara-C concentra­
tions for three patients. 
Fig 2b. The curves of Fig 2a are represented as double reciprocal plots which 
allow calculation of the V (from the intercept of the abscis) and of the 
К -equivalent (from the intercept of the ordinate). 
1/s, reciprocal concentration of ara-C; 1/v, reciprocal phosphorylation of ara-C. 
V
max (= niaxi'mal r a t e o f Phosphorylation) and a ^-equivalent (= concentration 
at which phosphorylation is half V
m
,J. Examples are shown in Fiq 2. 
At an ara-C concentration of 40 μΜ the phosphorylated and intracellularly 
entrapped ara-C sometimes appears to be less than at a concentration of 10 μΜ. 
The reproducibility of the determination of phosphorylation is good 
(variation coefficient 7%, n=10). When in one patient different bone marrow 
samples, generally obtained on different days, are compared, data show a 
variation coefficient of 15% (n=ll). 
The ^-equivalent values range from 1.1 μΜ to 16.2 μΜ (mean 4.2±2.8 μΜ, 
n=88) and the maximal phosphorylation V ranges from 18 to 190 pmol equi­
valents ara-C/10 cells after 30 minutes incubation (mean 66±32 pmol eq.ara-C/ 
10 cells, n=88). Independent of the extracellular ara-C concentration 
generally more than 50% (mean бЗ±1бг0 of the intracellular radioactivity is 
present as ara-CTP. Ara-UTP is not found in any sample. 
These findings imply a wide variation in the amount of ara-CTP, formed 
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during 30 minutes incubation with 1.1 μΜ ara-C, ranging from 2.1 to 28.7 
pmol ara-CTP/10 cells. 
Values of К -equivalent, V and percentage ara-CTP vary independently 
from each other and are not correlated with the percentage blast cells nor 
with the percentage S-phase cells. 
Dephosphorylation of ara-CTP 
Elimination of the intracellular radioactivity shows first order kinetics 
during the re-incubation period. The elimination time constants range from 
77 to 333 minutes, corresponding with half-life times of 53 to 210 minutes. 
The elimination rate is not affected by the intracellular ara-CTP content. 
The percentage radioactivity present as ara-CTP remains unchanged during the 
re-incubation period. 
Bone marrow samples of the same patient, obtained and tested on subsequent 
days, demonstrate good reproducibility of the results (variation coefficient 
11%). 
The radioactivity eliminated from the cells represents mainly ara-U 
(mean 75%, range 30 to 99%). 
Compariuon of phoephorylation in leukemic cells derived from bona marrou and 
from peripheral blood 
In 13 patients both bone marrow and peripheral blood are assayed. Values 
of К -equivalents show good similarity in 11 patients. However, drug 
accumulation is significantly lower in peripheral leukemic cells in 9 out of 
13 patients. The difference in phosphorylation between bone marrow and 
peripheral cells is not related to differences in percentage S-phase cells of 
the samples. 
Comparison of data from patients with AML and ALL 
Data of untreated patients with AML (n=40) and with ALL (n=12) are shown 
in Fig 3. Phosphorylation characteristics (K-equivalent, V
m
, . % ara-CTP, 
m ΠΊαΧ 
ara-CTP formation at 1.1 yM ara-C) show the same range in both types of 
leukemia, but dephosphorylation of ara-CTP is slower in lymphoblasts. 
Relation of in vitro assay with treatment response in AML 
The response to the first remission induction course in patients with 
newly diagnosed AML is compared to the in vitro phosphorylation activity of 
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Fig 3. Characteristics of (de-)phosphorylation of ara-C in leukemic bone 
marrow cells of untreated patients, grouped according to diagnosis. 
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia. 
(a) Km, equivalent of Michael is-Menten constant for phosphorylation of ara-C 
(b) V
m a x
, maximal amount of ara-C phosphorylated by 106 cells in30 minutes 
(c) percentage of intracellular radioactivity present as ara-CTP 
(d) amount of ara-CTP formed in 106 cells after 30 min incubation with 1.1 μΜ ara-C 
(e) Τ i(ara-CTP)' h a l f - l i f e time of el imination of i n t r a c e l l u l a r ara-CTP 
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Fig 4. Characteristics of (de-)phosphorylation of ara-C in leukemic bone 
marrow cells of untreated patients with acute myeloid leukemia, grouped 
according to response to the first remission induction course. 
NE, not évaluable; CR, complete remission; PR, partial remission; R, response; 
F, failure. 
(a) Km-equivalent; (b) щах; (c) Ti(ara-CTP) : see Fig 3. 
(d) percentage S-phase cells in the bone marrow sample 
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TABLE 1 
DATA FOR PHOSPHORVLATION OF ARA-C AND FOR DEPHOSPHORYLATION OF ARA-CTP OF UNTREATED PATIENTS IN COMPARISON 
WITH THOSE OF RELAPSED PATIENTS 
іЫгепІе tri.tu асліе гчуеісга сеакетіа 
% S-phase c e l l s 
K
m
 ( μ Μ ) 
ш« ( P ^ V I O c e l l s in 30 min) 
i rad ioact i v i ty in ara-CTP fract ion 
Ara-CTP uptake at 1.1 uM ara-C 
(pmol/106 c e l l s in 30 mm) 
THara-CTP) < m , n > 
Patients with acute lymf hoc laotia leukema 
% S-phase c e l l s 
K
n
 (PM) 
V
max (PmoVlo" c e l l s in 30 mm) 
% rad ioact i v i ty in ara-CTP fract ion 
Ara-CTP uptake at 1.1 gM ara-C 
(pmol/lO' c e l l s in 30 mm) 
u.r 
η 
38 
40 
40 
25 
40 
18 
11 
12 
12 
7 
12 
rLUlea patients 
meant s .d. 
1 0 . 7 x 3 . 4 
4 . 1 ± 2 . 2 
5 8 i 2 9 
64 ± 1 0 
1 3 . a ± 6 . 3 
103 ± 27 
1 8 . 2 t 7.2 
4 . 4 ± 3 . 1 
5 9 * 2 6 
73 ± 1 5 
1 4 . 6 ± 0 . 9 
range 
3 . 4 - 2 0 . 1 
1 . 1 - 11.1 
20 - 188 
4 9 - 9 0 
2 . 8 - 2 9 . 7 
56 - 147 
8 . 8 - 3 2 . 7 
1 . 4 - 1 1 . 6 
2 1 - 9 9 
4 9 - 8 9 
3 . 5 - 3 2 . 1 
tei 
η 
19 
21 
21 
IB 
21 
5 
12 
13 
13 
10 
13 
apgea p a t i e n t s 
mean ± s .d . 
1 0 . 5 * 3 . 3 
4 . 2 1 3 . 5 
86 ± 3 4 
64 ι 11 
2 2 . 5 * 9 . 9 
100 * 39 
1 9 . 4 * 9 . 2 
4 . 5 * 3 . 0 
6 5 * 3 4 
6 9 * 10 
1 5 . 2 * 9 . 9 
range 
5 . 5 - 18.5 
1 . Э - 1 6 . 2 
29 - 190 
4 9 - 7 7 
5 . 6 - 4 3 . 4 
5 3 - 1 3 1 
7 . 4 - 3 2 . 8 
1 . 1 - 1 0 . 8 
41 - 130 
4 8 - 8 3 
3 . 9 - 4 2 . 3 
Κ , equivalent of Michaelis-Menten constant 
с 
"max' m a ) < 1 m a ' amount of ara-C phosphorylated by 10 cells in 30 minutes 
Ara-CTP uptake at 1.1 μΜ ara-C, amount of ara-CTP formed by 10 cells a f t e r 30 mm incubation with 1.1 μΜ ara-C 
*4(ara-CTP)' h a ' f " ' l f e t 1 " * of elimination of intracel lular ara-CTP 
their leukemic cells. Phosphorylation tends to be lower in patients who fail 
to improve on the therapy. Cytokinetic data are not correlated to the 
treatment results. The data are demonstrated in Fig 4. 
Comparison of data of untreated and relapsed patients (table 1) 
Data obtained in patients with untreated and relapsed ALL are comparable. 
In patients with relapsed AML the phosphorylation activity seems increased, 
whereas the percentage S-phase cells, К -equivalent, percentage ara-CTP and 
dephosphorylation rate remain comparable. The change is even more pronounced 
in the results obtained in 8 patients with AML, who are assayed both at 
diagnosis and at a subsequent relapse (Fig 5). In 5 of them a marked increase 
in v
m
,^ is observed and in 7 patients ara-CTP formation at 1.1 uM ara-C is 
ΓΠαΧ 
increased. Furthermore, in 6 out of 8 patients a decrease in the К -equivalent 
is observed. This change is not unmasked when comparing the total groups of 
untreated and relapsed patients. 
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(o) <b) (с) 
Fig 5. Characteristics of phosphorylation of ara-C in leukemic bone marrow 
cells of eight patients, studied both at diagnosis (U) and at relapse (R). 
Data of each patient are connected.
 fi (a) Kro-equivalent; (b) V
m a
x; (c) ara-CTP in 10 cells after 30 min incubation 
with 1.1 μΜ ara-C. 
U, untreated; R, relapsed. 
DISCUSSION 
The good correlation between ara-C resistance and decreased ara-CTP 
formation in leukemic cell lines and animal tumors [8, 9, 22] has led to the 
determination of ara-C phosphorylation in human leukemic cells. However, the 
results are rather conflicting. The differences found in the intracellular 
quantity of ara-CTP formed at the same ara-C concentration, are very large. 
Furthermore, the association between high ara-CTP production and good clinical 
response, reported by Kessel et al [15] and Chou et al [37], was not confirmed 
by Smith et al [33]. These discrepancies may be due to the origin of the 
leukemic cells used, since peripheral blood cells differ from bone marrow 
derived cells in metabolic and cytokinetic properties [37, this study]. In 
none of the previous papers, peripheral blood admixture in the bone marrow 
samples has been taken into account. 
Ara-C phosphorylation appears to be a saturable process. The К -equivalents 
of ara-C range from 2-10 μΜ and are slightly lower than those reported for 
purified deoxycytidine kinase [14, 18, 19]. The decrease in ara-CTP formation 
using ara-C concentrations above 10 μΜ may be caused by cell lysis during 
66 
incubation, although substrate inhibition can not be excluded [21]. 
A wide range in ara-CTP formation is found in leukemic cells. These 
variations can not be explained by differences in percentage proliferating 
cells. In view of the dependence of deoxycytidine kinase activity on the 
cell cycle [45], an identical ara-C phosphorylation rate in all cells is 
unlikely. A higher amount of ara-CTP in 10 cells may be caused by a higher 
intracellular accumulation of ara-CTP in each cell, or by an increased 
fraction of cells involved in ara-C phosphorylation. Both effects may 
attribute to the favourable relation between high ara-CTP values and thera­
peutic effect. 
Ara-C is rapidly eliminated from the blood: half-life times range from 11 
to 33 minutes. Since ara-CTP is more slowly eliminated from the leukemic cells, 
the effect of ara-C will sustain much longer. The slow elimination of ara-CTP 
may also produce a delayed cell kill of cells not in S-phase at the moment of 
drugadministration but accumulating ara-CTP. These cells may be killed when 
they enter S-phase later on. 
In relapsed patients with AML ara-CTP formation is enhanced without an 
increased rate of dephosphorylation. So, failure of ara-C treatment, often 
seen in relapsed patients, seems not to be caused by impaired ara-CTP 
formation or retention. 
Literature about ara-C phosphorylation in lymphoblasts is conflicting. 
High kinase activities have been found in lymphoid cells [20, 24]. Kessel et 
al [15] found the same range of ara-CTP formation in lymphoblasts and myelo­
blasts, whereas Chou et al [37] reported significantly lower levels of 
ara-CTP in lymphoblasts. In the present study phosphorylation properties 
found in lymphoblasts and myeloblasts are similar. Dephosphorylation appears 
to be slower in lymphoblasts. In patients with relapsed ALL (who have not 
been treated previously with ara-C) intracellular metabolism of ara-C seems 
unchanged. 
Based on the results of this study, the following conclusions can be made: 
- Ara-C phosphorylation is saturated at concentrations higher than 5-10 μΜ. 
Therefore, high ara-C concentrations will not result in an increased rate 
of ara-CTP accumulation. 
- Elimination of the intracellular ara-CTP is slow in comparison to the 
elimination of ara-C. Consequently, the time course of the intracellular 
ara-CTP (and of the intracellular effect ) will be quite different from 
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the plasmaconcentration curve of ara-C. The pharmacokinetics of ara-CTP is 
probably clinically more relevant, at least in previously untreated patients. 
- An enhanced phosphorylation of ara-C is observed in patients with relapsed 
AML after previous ara-C treatment. Hence, treatment failure in these 
patients can not be explained by impaired ara-CTP accumulation. 
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ABSTRACT 
The cytocidal e f f e c t of cytosine arabinoside (ara-C) is exerted presumably 
by the i n t r a c e l l u l a r metabolite cytosine arabinoside triphosphate (ara-CTP). 
Ara-CTP is a competitive i n h i b i t o r of DNA-polymerizing enzymes, result ing in 
i n h i b i t i o n of the DNA synthesis. The ef fect of ara-C on the DNA synthesis can 
3 
be quant i f ied by measuring the i n h i b i t i o n of Η-thymidine incorporation. 
3 
The i n h i b i t i o n of Η-thymidine incorporation caused by various ara-C 
concentrations (0.0004 to 10 μΜ) has been measured in v i t r o in leukemic cel ls 
of 55 pat ients. The i n h i b i t i o n percentage, caused by a certain ara-C concen­
t r a t i o n , varies largely between individual pat ients. This var iat ion can be 
explained p a r t i a l l y by differences in ara-CTP formation. 
In leukemic ce l ls of patients with acute myeloid leukemia, 50% i n h i b i t i o n 
is observed at ara-C concentrations ranging from 0.003 to 0.15 μΜ. Tenfold 
higher ara-C concentrations are necessary to produce 90% i n h i b i t i o n . 
3 
Η-thymidine incorporation is more sensit ive to ara-C in lymphoblasts than 
in myeloblasts. I n h i b i t i o n in previously untreated and in relapsed patients 
appears to be comparable. 
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INTRODUCTION 
The chemotherapeutic effect of cytosine arabinoside (ara-C, 1-ß-D-arabino-
furanosylcytosine) is based predominantly on the interference of its 
phosphorylated metabolite cytosine arabinoside triphosphate (ara-CTP) with 
the cellular DNA synthesis [1, 2, 3, 4, 5]. Consequently, the cytostatic 
action of ara-C is directed to cells traversing the cell cycle [6, 7, 8]. 
It is supposed that marked and prolonged inhibition of the DNA synthesis 
leads to cell-death [9, 10, 11, 12]. 
Ara-CTP exerts its action as competitive inhibitor to cellular deoxycytidine 
triphosphate (dCTP) for DNA polymerases [3, 5, 13, 14, 15]. So, the inhibitory 
effect of ara-CTP on the DNA synthesis of cells is dependent on the size of 
the intracellular pool of dCTP [16, 17, 18]. Alterations in the affinity of 
ara-CTP for DNA polymerases may also result in a decreased activity of ara-C 
on the cellular DNA synthesis [19]. 
3 
Nuclear incorporation of Η-labeled thymidine can be used in order to 
measure the DNA-synthesizing activity of cells [20]. The same method has 
been used to quantify the effect of ara-C on the DNA synthesis of cells in 
vitro [21, 22]. 
In this chapter the in vitro effect of ara-C on the thymidine incorporation 
of leukemic bone marrow cells is described. Bone marrow samples of patients 
with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are 
investigated. Simultaneously the phosphorylation of ara-C in leukemic cells 
is quantified in order to investigate whether variations in the inhibitory 
effect of ara-C on the DNA synthesis, are related to differences in ara-CTP' 
formation. 
MATERIALS AND METHODS 
Patients and preparation of leukemic cell suspensions 
Bone marrow specimens are obtained from 39 patients with acute myeloid 
leukemia (28 newly diagnosed, 11 relapsed) and from 16 patients with acute 
lymphoblastic leukemia (6 newly diagnosed, 10 relapsed). Samples are collected 
in buffered acid citrate dextrose solution (ACD formula A, pH 7.4) and washed 
once in ACD in order to prevent fibrin formation during incubation. Only 
samples containing less than 25% peripheral blood admixture [23, chapter 9] 
and more than 60% leukemic cells are analysed. Washed cell samples are diluteú 
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in medium 199 (Flow Laboratories) buffered with 10 mM Tris (pH 7.4 at 37UC) 
and supplemented by 10% heat-inactivated f e t a l cal f serum (Flow Laboratories) 
to a c e l l concentration of 1-2 χ 10 cel ls/ml. 
Measurement of H-thyrmdtne гпсогрогаігоп ana irihtbitory effect of ara-C 
Aliquots of 1 ml of the c e l l suspension are incubated without and with 
ara-C ( f i n a l ara-C concentration ranging from 0.0004 to 10 yM). After 
incubation at 37 С during 30 minutes, 2 y d H-thymidine (Radiochemical 
Centre Amersham, specif ic a c t i v i t y 5 Ci/mmol) is added to each tube and 
incubation is continued f o r another 60 minutes. Incorporation is stopped by 
addit ion of 2 ml ice-cold medium with excess of unlabeled thymidine. Cells 
are collected on glass f i b r e f i l t e r s (Schleicher and Schui l , no. 9 ) , washed 
and lysed with water, and precipitated with IM perchloric acid [ 2 4 ] . The 
prec ip i ta te is dissolved in Lumasolve (Lumac). After addit ion of s c i n t i l l a t i o n 
f l u i d (Lipoluma, Lumac) the t o t a l amount of r a d i o a c t i v i t y is quantif ied in a 
l i q u i d s c i n t i l l a t i o n counter (LKB 81000) with a counting eff ic iency of about 
3 
30%. I n h i b i t i o n of Η-thymidine incorporation by ara-C is expressed as 
percentage of incorporation without ara-C. Incubation without ara-C is 
performed in f o u r f o l d (var iat ion coeff ic ient less than 5%), and incubation 
with addit ion of ara-C in duplicate (var iat ion c o e f f i c i e n t from 2 to 10%). 
Ara-C concentrations resul t ing in 50^ and 90% decrease of the thymidine 
incorporation are calculated from semi logarithmic plots of concentration versus 
i n h i b i t i o n percentage of thymidine incorporation. 
Measurement of percentage S-phase cells ыгік DNA-flowcytometry (DNA-FCM) 
A sample of each c e l l suspension is stained with hypotonic ethidium-
bromide according to Krishan [25] and the r e l a t i v e amounts of c e l l u l a r DNA in 
individual ce l ls are determined with an ICP-11 pulse cytophotometer (Phywé, 
Gottingen). The percentage of cel ls in S-phase is calculated from the 
obtained histograms [26, 27] . 
Measurement of ъп vitro phosphorylatton of ara-C гп leukemic cells 
Phosphorylation a c t i v i t i e s of the leukemic c e l l s are measured in v i t r o by 
3 
incubating the ce l ls with various concentrations H-ara-C and subsequent 
determination of the quantity ara-CTP formed. This method is described in 
deta i l in chapter 5. 
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TABLE 1 
VTHYMIDINE INCORPORATION AND PERCENTAGE 5-PHASE CELLS IN LEUKEMIC BONE MARROW CELLS 
Diagnosis* 
AML, Untreated 
AML, Relapsed 
ALL, Untreated 
ALL, Relapsed 
η 
20 
15 
6 
11 
mean ± s . d . 
range 
mean ± s . d . 
range 
mean ± s . d . 
range 
mean ± s . d . 
range 
H- thymidine 
i n c o r p o r a t i o n 
(dpm/106 c e l l s ) 
11417 ±5639 
3422-23153 
9173i5835 
2100-23108 
20597± 13753 
5530-43283 
12847 ±8120 
2315-25638 
% S-phase c e l l s " 
1 0 . 1 ± 3 . 1 
4 . 1 - 16.1 
9 . 6 ± 3 . 0 
5 . 5 - 17.9 
1 8 . 5 ± 8 . 7 
8 . 8 - 3 2 . 4 
1 8 . 9 ± 1 0 . 7 
3 . 6 - 32.8 
C o r r e l a t i o n 
c o e f f n 
0.72 
0.45 
0.43 
0.66 
c i e n t · * · 
p-value 
<0.0O5 
N . S " " 
N . S " " 
<0.025 
*AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia 
••Determination by DNA-flowcytometry 
•••Correlation between 'H-thymidine incorporation and corresponding % S-phase cells 
••••N.S., not significant 
RESULTS 
3 
Incorporation of H-thymidine in leukemic cells 
3 
The whole procedure for the determination of H-thymidine incorporation 
(wash-procedure, cell counting, preparation of cell suspension and dilutions) 
of a single bone marrow specimen is highly reproducible (variation coefficient 
6%, n=12). Data of multiple bone marrow aspirates, obtained on subsequent 
days from the same patient, show larger differences (variation coefficients 
up to 20%). 
3 
The Η-thymidine incorporation varies considerably between individual 
3 
patients. In previously untreated patients with AML incorporation of H-
thymidine is correlated to the percentage S-phase cells (DNA-FCM)(r=0.72, 
ρ<0.005). For patients with relapsed disease, and for patients with ALL, the 
results of the measurements correlate less well. Details are given in table 1. 
Effect of cœa-C on ' Η-thymidine incorporation 
Some examples of the relationship between ara-C concentration and inhibition 
of thymidine incorporation are shown in Fig 1. Pre-incubation of 30 minutes 
turns out to be sufficient. After 90 minutes pre-incubation inhibition 
percentages are only slightly higher than those measured after a pre-incubation 
75 
0.0001 0,001 0.01 0.1 1,0 10 
concentration ara-C (μΜ) 
Fig 1. Effect of increasing ara-C concentrations on the Η-thymidine incor­
poration of leukemic bone marrow cells of three d i f f e r e n t patients. 
period of 30 minutes (1.03 times higher, n=10). 
I n h i b i t i o n percentages are highly reproducible wi th in the same pat ient. 
In б patients studies are performed on subsequent days. The variat ion co­
e f f i c i e n t of the i n h i b i t i o n percentage at the same ara-C concentration varies 
from 2 to 11%. 
I n h i b i t i o n of thymidine incorporation by ara-C varies considerably between 
individual pat ients. Ara-C concentrations producing 50% i n h i b i t i o n range from 
0.003 to 0.13 yM. To produce 90% inh ib i t ion of thymidine incorporation, ara-C 
concentrations from 0.02 to 8 yM are required. In 5 patients i t is impossible 
to i n h i b i t thymidine incorporation for 90%. These data are shown in Fig 2. 
Thymidine incorporation in lymphoblasts seems to bemore sensitive to ara-C 
in comparison to myeloblasts (Fig 2). In relapsed pat ients, thymidine incor­
poration also tends to be inhib i ted at lower ara-C concentrations. 
The e f f e c t of incubation with 0.01, 0.04 and 0.1 yM ara-C in a l l pat ients, 
grouped according to diagnosis, is depicted in Fig 3. The i n h i b i t i o n percen­
tages obtained at each ara-C concentration vary. Largest differences are 
found at an ara-C concentration of 0.04 yM. 
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1.0 
0.1 
0.01 
0.001 
10 -
1.0 -
0.1 
0.01 
Fig 2. Ara-C concentrations which produce 50% (a) or 90% (b) i n h i b i t i o n of 
the Зн-thyniidine incorporation of leukemic bone marrow c e l l s . 
Data are grouped according to diagnosis. 
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; U, untreated; 
R, relapsed. 
Effect of ara-CTP on thym-idine incorporation 
Intracellularly entrapped ara-CTP (in 10 cells) corresponding to 50% 
inhibition of the thymidine incorporation, ranges from 0.04 to 1.12 pmol in 
myeloblasts and from 0.02 to 0.33 pmol in lymphoblasts (table 2). Since a 
pronounced inhibition of the DNA synthesis is required to cause cell-death, 
ara-CTP levels which lead to 90% inhibition of the thymidine incorporation 
are probably more relevant. The quantities of ara-CTP producing 90% inhibition, 
range from 1.1 to 12.0 pmol/10 cells for myeloblasts, and from 0.2 to 2.9 
pmol/10 cells for lymphoblasts (table 2). In untreated patients with AML the 
amount of ara-CTP, resulting in 90% inhibition of the thymidine incorporation 
correlates with the percentage cells in S-phase (correlation coefficient 0.54, 
ρ <0.02). In relapsed patients slightly less ara-CTP per 10 cells is required 
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Fig 3. Effect of three ara-C concentrations (0.01, 0.04 and 0.1 μΜ) on the 
Зн-thyniidine incorporation of leukemic bone marrow cells. 
Data are grouped according to diagnosis. 
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; U, untreated; 
R, relapsed. 
TABLE 2 
AMOUNT OF ARA-CTP WHICH PRODUCES 50% AND 90« INHIBITION OF 3H-THYMIDINE INCORPORATION 
Diagnosis* 
AML, Untreated 
AML, Relapsed 
ALL, Untreated 
ALL, Relapsed 
so;. 
η 
24 
16 
6 
11 
inhibition 
meant s.d. 
range 
mean ι s.d. 
range 
mean ± s.d. 
range 
mean ± s.d. 
range 
amount of ara-
(pmol/106 cell 
0.44 ±0.27 
0.04-1.12 
0.28*0.14 
0.09-0.49 
0.24±0.08 
0.10-0.33 
0.11*0.06 
0.02-0.16 
CTP 
s) 
90% 
η 
20 
15 
6 
11 
inhibition 
mean * s.d. 
range 
mean * s.d. 
range 
mean * s.d. 
range 
mean * s.d. 
range 
amount of 
(pmol/106 
4.8*2.8 
1.1- 12.0 
3.1*1.4 
1.3-6.3 
1.9*0.7 
0.9-2.9 
1.1*0.7 
0.2-2.2 
ara­
celi 
CTP 
s) 
p-value" 
<0.02 
N.S"· 
*AML, acute myeloid leukemia, ALL, acute lymphoblastic leukemia 
••Comparison of data between untreated and relapsed patients (Milcoxon test) 
•**N.S., not significant 
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TABLE 3 
RELATION BETWEEN PERCENTAGE INHIBITION OF 3H-THYMIDINE INCORPORATION AND FORMATION OF ARA-CTP 
AT DIFFERENT CONCENTRATIONS OF ARA-C 
Diagnosis» 
AML, Untreated 
AML. Relapsed 
ALL, Untreated 
ALL, Relapsed 
Concentration 
of ara-C 
(ьМ) 
O.OIO 
0.041 
0.10 
0.010 
0.041 
0.10 
0.010 
0.041 
0.010 
0.041 
π 
23 
23 
23 
16 
16 
16 
6 
6 
10 
10 
» inhibit ion 
range 
0-66 
16-88 
43-95 
0-60 
24-88 
46-93 
21-66 
58-91 
37-81 
73- 100 
amount of ara-CTP 
(pmol/106 cel ls) 
range 
0.02-0.34 
0.07- 1.35 
0.17-3.18 
0.03-0.47 
0.15- 1.92 
0.35-4.40 
0.07-0.33 
0.29-1.37 
0.01-0.31 
0.18- 1.27 
Correlation 
coefficient*» 
0.51 
0.52 
0.59 
0.10 
0.05 
0.13 
0.54 
0.68 
0.45 
0.50 
p-value 
<0.01 
<0.005 
<0.005 
N.S"* 
N
'
s ; " 
N.S!** 
N.S*" 
N.S*" 
N
-C 
N.S!" 
»AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia 
•»Correlation between % inhibition of 3H-thymidine incorporation and corresponding amount of ara-CTP 
»»»N.S., not significant 
for the same effect. 
In untreated AHL patients, inhibition of thymidine incorporation correlates 
to ara-C phosphorylation (table 3). This correlation is not found in relapsed 
patients. The number of studies performed in ALL patients is too small for 
more detailed evaluation. 
Relation between -in vitro effect of ara-C on DNA synthesis and response to 
therapy in patients with acute myeloid leukemia 
Twenty-one patients with newly diagnosed AML are treated with the same 
? 
remission induction therapy. Treatment consists of adriamycin (50 mg/m i.V., 
2 2 
day 1), vincristine (1.0 mg/m i.V., day 2) and ara-C (80 mg/m i.V. twice 
daily, day 3-8). Three patients decease during treatment or shortly thereafter, 
and are considered not évaluable. All patients with an inhibition percentage 
of more than 75% at 0.1 μΜ ara-C obtain a complete remission. Five out of 
10 patients with lower inhibition percentages fail to therapy (table 4). 
Of 5 patients with AML (4 untreated, 1 relapsed) in whom even a high ara-C 
concentration ( > 1 μΜ) does not induce 90% inhibition of the thymidine 
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TABLE 4 
RELATION BETWEEN 
» inhibition 
at 0.1 μΜ ara-C 
ì 75 
< 75 
INHIBITION OF 3H-TH1ÍMIDINE INCORPORATION 
η 
9 
12 
Not évaluable Evaluable 
1 8 
2 10 
IN VITRO AND RESPONSE TO 
Complete Failure 
remission 
β 0 
5 5 
THERAPr 
p-value* 
<0.02 
*X -test 
incorporation one patient deceases before therapy is started, three patients 
are refractory to therapy, and one patient, who is treated with high-dose 
chemotherapy, attains a complete remission. 
DISCUSSION 
Large individual variations in the inhibition of thymidine incorporation 
by leukemic cells by ara-C have been reported previously. Part of these 
studies has been performed after ara-C administration in vivo [28, 29, 30] and 
is difficult to interprete in view of the attributing pharmacokinetic 
variations. Data of in vitro incubations, as reported in literature [31, 32, 
33, 34, 35], are hard to compare. Often only one or two ara-C concentrations 
have been tested and results obtained in untreated and relapsed patients have 
not been considered separately. Furthermore, the quality of bone marrow 
samples has never been taken into account. The data given in the present 
study confirm the variable effect of ara-C on the thymidine incorporation by 
leukemic cells of individual patients. 
In patients with untreated asuLe myeloid leukemia inhibition measured in 
vitro seems to be related to in vivo efficacy. High inhibition percentages 
are associated with better therapeutic results. The inhibitory effect of 
ara-C on the leukemic cells of untreated patients with AML is established 
to be related to the extend of cellular ara-C phosphorylation. Harris et al 
[35], studying a limited number of patients, have not found this correlation. 
However, substantial interindividual variations are observed in amount of 
ara-CTP producing similar inhibition of thymidine incorporation (table 3), 
which may be explained partially by differences in percentage S-phase cells. 
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Variations in the intracellular pool of deoxycytidine triphosphate or in the 
number of non-S-phase cells phosphorylating ara-C (see chapter 7) may also 
account for this discrepancy. The quantity of ara-CTP inducing 50% inhibition 
of the thymidine incorporation ranges from 0.04 to 1.12 pmol ara-CTP/10 cells, 
confirming the data reported by Harris et al [35]. A 90% inhibition requires 
ara-C concentrations from 0.06 to 8 yM, corresponding with 1.1 to 12.0 pmol 
ara-CTP/ 106 cells. 
In patients with relapsed acute myeloid leukemia, thymidine incorporation 
is as effectively blocked as in untreated patients. Contrasting with untreated 
patients, inhibition of thymidine incorporation by ara-C shows no relation 
with phosphorylation of ara-C, nor with percentage S-phase cells. 
The number of studies performed in patients with aaute lymphoblastic 
leukemia is rather small. Thymidine incorporation in lymphoblasts seems to be 
more sensitive to ara-C in comparison to myeloblasts. Inhibition of 90% is 
achieved in all patients (untreated and relapsed) at ara-C concentrations of 
about 0.1 μΜ, corresponding with intracellular amounts of ara-CTP from 0.2 to 
2.9 pmol ara-CTP/10 cells. Similar quantities ara-CTP are required to inhibit 
DNA synthesis of a human lymphoblastic cell line [36]. 
In conclusion: the influence of ara-C on in vitro thymidine incorporation 
by leukemic cells varies considerably. Lymphoblasts seem more sensitive than 
myeloblasts. To produce 90% inhibition of thymidine incorporation in the 
majority of patients, an ara-C concentration of 1 μΜ is required in AML, 
whereas in ALL 0.1 μΜ ara-C will be adequate. In previously untreated patients 
with AML, the in vitro effect of ara-C seems of predictive value for the 
sensitivity in vivo. The less favourable response to ara-C therapy in relapsed 
patients is not easily explained by the present in vitro experiments. 
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ABSTRACT 
Bone marrow cells of 5 patients with acute myeloid leukemia have been 
separated in subpopulations by means of counterflow centri fugati on (elutriation). 
3 
Cytokinetic evaluation of each fraction is performed by H-thynndine auto-
3 
radiography, Η-thymidine incorporation and DNA/RNA flowcytometry. 
Each fraction appears to be enriched with cells belonging to subsequent 
phases of the cell cycle. 
Cellular phosphorylation of cytosine arabinoside (ara-C) is determined by 
3 
incubation of the cells with 1.1 μΜ H-ara-C. Ara-C phosphorylation ranges 
from 5.9 to 33.2 pmol/10 cells in 30 minutes in the unseparated samples. In 
elutriation fractions with G^phase cells only, phosphorylation ranges from 
1.2 to 19.2 pmol/10 cells in 30 minutes. Ara-C phosphorylation increases in 
fractions preceeding those enriched with S-phase cells. Maximal activities 
are found in fractions enriched with late G,- and S-phase cells and range from 
8.8 to 36.9 pmol/106 cells. 
Since elimination of ara-CTP is a rather slow process (half-life times of 
1 to 3 hours), the number of Gj-phase cells killed by ara-C may be an 
important variable for the efficacy of ara-C treatment. 
Since elimination of ara-CTP is a rather slow process (half-life times of 
1 to 3 hours), part of the G,-phase cells may still retain cytotoxic amounts 
of ara-CTP when entering S-phase. The number of G,-phase cells killed by 
ara-C may be an important variable for the efficacy of ara-C treatment. 
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INTRODUCTION 
Cytosine arabinoside (ara-C, l-ß-D-arabinofuranosylcytosine) is a powerful 
cytostatic agent for the treatment of acute myeloid leukemia Ш . After intra­
venous administration the bulk of the drug is rapidly deaminated to the 
inactive metabolite uracil arabinoside (ara-U, 1-ß-D-arabinofuranosyluracil) 
[2, 3]. In the leukemic cells ara-C is simultaneously phosphorylated to 
cytosine arabinoside triphosphate (ara-CTP) [3, 4, 5]. The rate limiting step 
is the first phosphorylation-step catalyzed by deoxycytidine kinase [6]. The 
phosphorylating capacity seems to be restricted mainly to the S-phase, as has 
been demonstrated in synchronized cell-cuitures [7, 8]. Ara-CTP is a competi-
tive inhibitor of deoxycytidine triphosphate for the DNA-polymerizing enzyme 
[4, 9]. Therefore, it is generally accepted that ara-C is a S-phase specific 
drug,killing leukemic cells during the DNA-synthesis-phase only [5, 10, 11, 
12, 13]. 
There is a slight indication, that ara-C is also phosphorylated by human 
myeloid leukemic cells during the G,-phase of the cell cycle [14]. Later on, 
these cells may be killed when they enter the S-phase, provided that ara-CTP 
is maintained intracellularly long enough. Four hours after incubation with 
ara-C, 10 to 70% of the ara-CTP is still entrapped within the leukemic cells 
[15, chapter 5]. Consequently, the number of cells, damaged by ara-C may be 
much higher than the number of cells in S-phase at the moment of drug 
administration. 
The determination of the phosphorylating capacity of leukemic cells has 
always been performed on unperturbed leukemic cell populations [16, 17, 18, 19]. 
No data are available concerning changes in ara-C phosphorylation during the 
sequential phases of the cell cycle of human leukemic cells. Knowledge about 
the percentage of cells phosphorylating ara-C is completely lacking. Insight 
in these phenomenons can be gained by studying synchronously growing cell 
populations. 
All methods to procure synchronized cell populations [20] require rather 
long-lasting incubation periods. Therefore, these methods are not applicable 
in human leukemia. Counterflow centrifugation (elutriation) offers the 
possibility to obtain fractions enriched with cells of various phases of the 
cell cycle [14, 21]. The sub-populations are procured in a short time period 
and the cells show no loss of viability [21, 22]. 
In this chapter the fractionation of freshly aspirated human leukemic bone 
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marrow cells and of a human leukemic cell-line (RPMI 1788) by means of counter-
flow centrifugation is described. The subpopulations represent subsequent 
stages of the cell cycle, as is demonstrated by reculturing the elutriation 
fractions of the cell-line. The fractions are cytokinetically monitored by 
DNA-RNA-flowcytometry [23], Η-thymidine incorporation and autoradiography. 
Phosphorylation of ara-C is found not only in S-phase cells, but also in cells 
in G^-phase. These observations may provide more knowledge about the fraction 
of cells killed by ara-C and may offer a new determinant in the individual 
variation of the antileukemic effect of ara-C treatment. 
MATERIALS AND METHODS 
PaticnLs and bone marrow samples 
Studies are performed in 5 patients with acute myeloid leukemia (table 1). 
Bone marrow aspirates are collected in buffered acid citrate dextrose solution 
(ACD formula A, pH 7.4). Cells are once washed in order to prevent fibrin 
formation during the incubation experiments. In 4 out of the 5 aspirates more 
than 50% of the nucleated cells really originates from the bone marrow compart­
ment, as calculated according to Holdrinet et al [25, 26]. 
Preparation of cell fractions by eounierflow aentrifugation 
Q 
Bone marrow specimens of about 10 cells are layered on a Ficoll-Isopaque 
density cushion (s.g. 1.085 g/ml) to remove erythrocytes. After centri fugati on 
(20 min, 1000g , 10oC) the cells are collected from the interface and washed 
in phosphate-buffered sodiumchloride solution (PBS, pH 7.4), supplemented with 
1% fetal calf serum (Flow Laboratories). The cell-suspension is then introduced 
(0.3 ml/min) into a Beekman Elutriator (J 2-21 centrifuge, equipped with a 
JE-6 rotor), spinning at 2200 rpm and at a counterflow of 9 ml/min. Cell-
elutriation is performed at 180C and is effectuated by stepwise increase of the 
counterflow to 30 ml/min. 
The elutriator effluent is continuously monitored by an electro-optical 
scatter unit, allowing control of cellnumber and relative cellsize of the 
elutriated cells [22]. Cells are collected and pooled to fractions, containing 
each at least 10 cells. After centri fugati on, the cellpellets are diluted in 
medium 199 (Flow Laboratories) buffered with 10 mM Tris (pH 7.4) and supple­
mented with 10% heat-inactivated fetal calf serum to a final cell concentration 
of 10 cells per ml. 
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TABLE 1 
HEMATOLOGICAL DATA OF PATIENTS 
Patient 
1 
2 
3 
4 
5 
Age 
(years) 
67 
56 
25 
64 
59 
Sex 
m 
f 
f 
f 
m 
Diagnosis* 
H 4 
M 1 
M 4 relapse 
M 2 
M 5 
» blasts in 
bone marrow 
91 
97 
91 
69 
86 
ывс*· 
(χ 1 0 9 Л ) 
422 
48.3 
10.7 
1.9 
93.2 
% blasts 
periphere 
100 
92 
68 
0 
94 
in 
1 blood 
% bone marrow cel ls 
in aspirate**· 
44 
74 
96 
99 
53 
•Classification according to the French-American-British (FAB) Co-operative Group Classification (Ref. 24) 
**WBC, white blood cell count 
•••Calculation according to Holdrlnet et al (Refs. 25, 26) 
Control experiment of cell cycle specific separation 
Cells of a human leukemic cell-line RPMI 1788 [27] are fractionated by 
9 
counterflow centrifugation. The large number of cells (10 cells) necessary 
for this experiment is elutriated by stepwise increase of the rotorspeed. To 
prevent disturbance of the cell cycle progression, elutriation is carried out 
at 37 С and the cells are kept in culture medium (RPMI 1640, supplemented with 
5 ID/ml penicillin and 5 lU/ml streptomycin, 20 μΜ glutamine, 10% fetal calf 
serum and buffered with bicarbonate at pH 7.4) during the whole procedure. 
о 
Samples are pooled to 6 fractions, each containing 1.0 to 1.5 χ 10 cells, and 
then recultured at 37 С in b% carbon dioxide in humidified air. The 
proliferation in each fraction is followed during 18 hours by measuring the 
increase in cellnumber, Η-thymidine incorporation, labelingindex, and two-
parameter DNA-RNA-flowcytometry at different time-intervals. 
Measurement of aytokinetic parameters 
3 
Measurement of labelingindex (L.I.). To 400 μΐ cell-suspension 5 μΟτ H-
thymidine (Radiochemical Centre Amersham, specific activity 5 Ci/mmol) is 
added and the samples are incubated for 60 min at 37 С After incubation, 
autoradiograms are prepared as described elsewhere [25, chapter 9]. The 
percentage labeled cells is determined by analysing at least 1000 nucleated 
cells. Cells with more than 5 grains are considered to be labeled. 
3 
Measurement of Η-thymidine incorporation. Four aliquots of 1 ml cell-
suspension (10 cells/ml) are incubated with 2 yCi Η-thymidine (specific 
activity 5 Ci/mmol) for 60 min at 370C. Incorporation of radioactivity is 
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stopped by adding 2 ml ice-cold medium with an excess of unlabeled thymidine. 
The cells are collected on glass fibre filters (Schleicher and Schuil no. 9), 
washed and precipitated with 1 M perchloric acid. The total amount of incor­
porated radioactivity is measured in a liquid scintillation counter (LKB 81000). 
The counting efficiency is about 30%. 
Measurement of relative cellular DNA and RNA content by flowcytometry (FCM). 
The nuclear DNA of about 10б cells of each cellsuspension is stained with 
hypotonic ethidiumbromide solution (0.1% tri-sodium citrate, 25 mg/1 ethidium-
bromide) according to Krishan [28]. The relative fluorescence of about 10 
individual cells is measured in a flowcytometer (ICP-11, Phywé, Göttingen, FRG). 
The fractions of cells in G,-, S-, or G?+M-phase are estimated by a computer-
program, based on the method described by Johnston [29]. 
The number of cells in early and late G^-phase is determined by a two-
parameter measurement of the cellular DNA and RNA content [23]. The cells are 
stained with acridine orange, essentially according to Tráganos et al [30]: 
0.2 ml of the cellsuspension is mixed with 0.4 ml of a Triton X-100 solution 
(0.05% Triton X-100 v/v, 0.15 M sodiumchloride, 0.1 M hydrochloric acid) at 
room temperature. Exactly 15 seconds later 1.2 ml of the staining solution is 
added. The staining solution consists of buffered saline (0.15 M sodiumchloride, 
buffered at pH 6.0 by the addition of 0.2 M di-sodiumphosphate and 0.1 M 
sodiumcitrate) containing 20 mg/1 acridine orange and 0.001 M EDTA. The 
measurements are done in a flowcytometer (ICP-11, Phywé) adapted for two-
parameter measurements. 
Phosphorylation of ara-C 
Samples of 1 ml of each cellsuspension are incubated for 30 min at 37 С 
3 
with 1.0 yM ara-C and 2 мСі H-ara-C (Radiochemical Centre Amersham, specific 
activity 28 Ci/mmol), final concentration 1.07 μΜ ara-C. The cells are then 
washed 4 times with 3 ml ice-cold PBS (pH 7.4), supplemented with 1% bovine 
albumine. The total amount of intracellular radioactivity is determined by 
transferring the cellpellet into 10 ml counting vials, containing 1 ml 
distilled water, adding 9 ml scintillation fluid (Instagel, Packard) and 
counting the radioactivity in a scintillation counter. For the determination 
of the percentage ara-CTP, the cellpellet is lysed with 0.5 ml 50% ice-cold 
ethanol-water solution. The extract is spotted on a PEI-cellulose F plate 
(E. Merck Ag, FRG) and separation of the mono-, di-, and triphosphates is 
achieved at 4 C, using as eluent 0.2 M ammonium-sulphate solution adjusted at 
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pH 7.0 [31, 32]. The mono-, di-, and triphosphate fractions are collected in 
counting vials with 4 ml 1 N hydrochloric acid and 6 ml scintillation fluid 
(Instagel) is added. The liquid scintillation counting efficiency of these 
samples is about 20%. 
RESULTS 
Recovery 
The recovery of the nucleated cells on the density cushion is satisfying 
(mean recovery 89%, range 70X to 90%). Elutriation produces only a minor cell-
loss (mean recovery 80%, range 64% to 90%). The summation of the number of 
S-phase cells present in the different fractions is comparable with the total 
number of S-phase cells in the unseparated sample. 
Cytokinetia data of (sub-)populations of human leukemia hone marrow cells 
Fractions obtained at successive flowrates contain cells with increasing 
cell-diameter [14]. This has been monitored by scatterpatterns and controlled 
by microscopic examination of the fractions. 
The separation data are given in table 2. Nearly all fractions contain more 
than 80% blast cells. The fractions leaving the elutriator rotor at the 
terminal stages of the procedure, are enriched with S-phase cells. An example 
of the DNA-histograms of one experiment (patient 2) is given in Fig 1. 
In the first fractions, leaving the elutriator rotor, a low but not negligable 
percentage (2-4%) S-phase cells has been found with DNA-FCM. However, label ing-
indices in these fractions do not exceed 1%. This discrepancy is caused by 
overestimation of the percentage S-phase in FCM, due to coincidence. In the 
later fractions, where the percentages S-phase cells exceed 4%, the data 
obtained with DNA-FCM and autoradiography are not significantly different. At 
higher values, FCM determinations are more accurate (relative error less than 
10%) than autoradiography (relative error about 15%)[25]. The H-thymidine 
incorporation of the fractions in each experiment correlates well with the 
percentages S-phase cells (correlation coefficients 0.90 to 0.98). Cells with 
2n DNA are separated in fractions, enriched with cells in early and late G,-
phase, as is demonstrated by the differences in their relative RNA-content 
(Fig 2)[23] and by the results of the cell-line experiment, described in the 
following paragraph. 
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TABLE 2 
SEPARATION DATA OF LEUKEMIC CELLS AND THEIR RELATION WITH ARA-C PHOSPHORYLATION 
Patient 
Unseparated 
bone marrow sample 
Elutnation flow·· 
10 11 12 13 14 IS 16 17 18 19 20 21 22 23 30 
cell number (X of total) 
morphology (X blast cells) 98 
labelinglndex (%) 17.6 
FCH· * S-phase cells 10.4 
% (Gj+MJ-phase cells , 0.2 
phosphorytated ara-C (pmol/10 cells) 5.9 
96 
0.3 
1.4 
0.2 
1.9 
12 
100 
0.3 
2.6 
0.2 
3.2 
22 
100 
0.3 
2.4 
0.1 
5.6 
14 
99 
0.9 
2.5 
0 
8.5 
13 
99 
4.6 
4.7 
0.2 
13.1 
12 
99 
10.0 
6.9 
0.5 
17.2 
11 
98 
36.7 
20.6 
1.6 
16.8 
94 
50.7 
11.4 
13.1 
cell number (% of total) 
morphology (% blast cells) 97 
labelingindex (%) 11.8 
FCM» % S-phase cells 5.6 
% (Gj+M)-phase cells
 6 2.1 
phosphorytated ara-C (pmol/10 cells) 13.9 
18 
98 
0.1 
1.9 
0.4 
8.5 
32 
96 
0.4 
1.7 
0.3 
10.4 
25 
99 
1.2 
2.0 
0.3 
14.5 
11 
94 
9.5 
8.1 
0.7 
17.4 22.8 
7 
94 
35.5 
35.4 
24.8 
29.7 
cell number (1 of total) 
morphology (I blast cells) 91 
labelingindex (%) 5.0 
FCM· X S-phase cells 8.1 
% (Gj+MJ-phase cells , 3.2 
phosphorytated ara-C (pmol/10 cells) 33.2 
7 
78 
0.4 
2.9 
0.7 
20.5 
13 
87 
0.5 
3.0 
0.4 
19.5 
12 
96 
0.5 
2.6 
0.4 
29 4 
22 
99 
0.9 
3.8 
0.2 
36.3 
13 
97 
3.9 
4.6 
0.2 
33.8 
19 
95 
7.6 
8.1 
2.7 
36.9 
9 
93 
13.0 
12.1 
5.8 
36.5 
5 
90 
26.0 
16.3 
16.6 
29.8 
cell number (X of total) 
morphology (X blast cells) 69 
labelingindex (X) 13.0 
FCM· X S-phase cells 14.7 
X (G2+H)-phase cells 6 3.1 
phosphorytated ara-C (pmol/10 cells) 6.3 
5 
14··· 
0.1 
1.2 
4 
21··· 
0.2 
2.4 
0.8 
1.4 
6 
72 
0.1 
1.8 
0.6 
1.7 
13 
87 
0.1 
2.8 
0.7 
2.4 
14 
86 
0.3 
2.5 
0.5 
3.2 
16 
95 
3.8 
3.5 
0.4 
4.5 
8 
38 
3.5 
4.4 
0.7 
4.3 
7 
74 
6.0 
11.5 
1.3 
4.8 
5 
84 
11.2 
11.9 
2.4 
7.0 
78 
18.6 
19.9 
5.4 
7.7 
6 
83 
35.7 
30.3 
12.0 
8.8 
8 
81 
52.0 
34.4 
26.3 
7.7 
cell number (X of total) 
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8 
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1.5 
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99 
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¿3.6 
4.9 
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12 
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18.7 
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•FCM, flowcytometry 
••flow (ml/min), at which cells are elutriated from centrifuge (see under Methods) 
•••fraction contained mainly lymphocytes 
fraction 6 
fraction 5 
pre-elutriation 
relative DNA content 
Fig 1. DNA-histograms (ethidium bromide s ta in ing, see under Methods) of bone 
marrow cel ls (patient 2) before and af ter e l u t r i a t i o n . 
relative DNA content 
Fig 2. Three-dimensional DNA-RNA contour-histograms (acridine orange sta in ing, 
see under Methods) of bone marrow cel ls (patient 2) before e lu t r i a t i on and of 
the early e lu t r i a t i on f ract ions. 
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Fig 3. Time course of Η-thymidine incorporation and cellnumber of unseparated 
RPMI-1788 cells and of the various elutriation fractions (see under Methods). 
Arrows indicate the moment of increase in cellnumber. 
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СуІокъпеігв evaluation of the elutriaiion fractions of the leukemia cell-line 
The time-course of the Η-thymidine incorporation of the different 
elutriation-fractions shows patterns that are typical for synchronously growing 
3 
cell-cultures (Fig 3.)[8]· The maximal value of the Η-thymidine incorporation 
in each fraction is reached about 3 hours earlier than in the preceeding 
fraction. This time-shift represents the difference between the fractions with 
respect to the cell cycle progression.This is confirmed by the moment at which 
the increase in cellnumber is registered (Fig 3.). The time between two 
subsequent maximal values of Η-thymidine incorporation of fraction 4 (Fig 3.) 
is about 16 hours and represents the cell cycle time. 
PhoephorylaLion of ara-C in (¡sub-)populations of leukemic cells 
The phosphorylation of ara-C in leukemic cells of each patient before and 
after elutriation is given in table 2. Phosphorylation is not altered by the 
elutriation procedure, since the mean phosphorylation calculated from the 
fractions, equals the phosphorylation found before separation. About 70% 
(range 60% to 80%) of the intracellular radioactivity appears to be ara-CTP. 
At a concentration of 1.07 uM ara-C, the phosphorylation in the unseparated 
bone marrow population during 30 min incubation,ranges from 5.9 to 33.2 
pmol/10 cells. The results of drug-uptake in the various successive fractions 
indicate that not all cells are equally involved in ara-CTP formation. The 
data demonstrate that phosphorylation of ara-C also occurs in G.-phase cells. 
Phosphorylation gradually increases in the subsequent fractions, with the 
highest activity found in fractions, probably enriched with late G,- and 
S-phase cells (table 2, Fig 4.). The maximal uptake of ara-C differs largely 
(range 8.8 to 36.9 pmol/10 cells) and shows some relation with the data of 
the unseparated cell-population. The relative increase of ara-C phosphorylation 
in the subsequent fractions varies in patients. This may be related to 
differences in separation-quality. 
DISCUSSION 
Ara-C treatment schemes do not result in the same response in all patients 
with acute myeloid leukemia [1]. Determinants for the antileukemic effect are: 
(a) the dose of ara-C; (b) the number of injections; (c) the deamination rate 
to arabinoside uracil (ara-U) by the liver; (d) the phosphorylating capacity 
of the leukemic cells and (e) the number of cells killed by each ara-C 
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Fig 4. Percentage S-phase cells ( · · ) and ara-C phosphorylation (o о ) 
in elutriation fractions (patient 1). 
injection [5, 12, 33, 34]. In animal tumors the number of cells killed by 
ara-C usually equals the number of S-phase cells [21, 35]. In studies with 
synchronized cell-cuitures, ara-C phosphorylation appeared to be restricted to 
S-phase cells [7, 8]. Up till now no data have been available about changes in 
the ara-C phosphorylation of intact human leukemic cells during the various 
phases of the cell cycle. In this study it is demonstrated that ara-C 
phosphorylation in human leukemia is not restricted to the S-phase. 
Using cell-elutriation, cell-populations can be separated in fractions, 
enriched with cells at specific phases of the cell cycle [14, 21]. As is shown 
in this study with the cell-line RPMI 1788,sub-populations of the Gj-phase can 
be obtained. The separation in early and late G,-phase can be monitored with 
two-parameter DNA-RNA-flowcytometry, as was demonstrated by Darzynkiewicz et 
al [23]. The separation-quality is partially wiped out by pooling of samples 
to larger fractions, which contain enough cells for the experiments. More 
optimal separation can be achieved when elutriation is carried out with 
smaller differences in the flowrate. Elutriation provides a useful method for 
the determination of the phase-specificity of cytostatic drugs, as was demon­
strated recently by Meyn et al [21] for various drugs with chinese hamster 
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ovary cells, and is also shown in this study for ara-C in human leukemia. 
The variation in drug-uptake, found between the patients, can not be 
explained by differences in cell-size of the blasts. 
The increase in phosphorylated ara-C, found in the subsequent fractions, 
is not proportional to the increase of the percentage S-phase cells. 
Especially the fractions, preceeding those enriched with S-phase cells, show 
high ara-C phosphorylating activity. These fractions contain hardly any S-phase 
cells, but are enriched with G,-cells with a relatively high RNA content. 
Obviously, ara-C phosphorylation is not restricted to the S-phase. Cells 
preparing for replication, so-called G,-b cells [23], are probably involved in 
ara-C phosphorylation to almost the same extend as S-phase cells.Part of these 
cells can be expected to be killed, when they enter the S-phase, since elimi-
nation of intracellular ara-CTP is a rather slow process [15, chapter 5]. The 
fraction of cells, killed by ara-C on account of this effect may differ 
between patients. This variation may be an important determinant in the indi-
vidual response to ara-C treatment. To calculate more accurately the number 
of cells damaged by a single ara-C injection, data as presented in this study 
have to be extended with data about (a) the duration of ara-CTP retention; 
(b) the rate of the cell cycle progression and (c) the intracellular amount 
of ara-CTP necessary for cell kill. 
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chapter 8 
DETERMINATION OF CYTOSINE ARABINOSIDE TRIPHOSPHATE IN LEUKEMIC CELLS 
BY HIGH PRESSURE LIQUID CHROMATOGRAPHY 
P. Linssen, A. Drenthe-Schonk, H. Wessels, G. Vierwinden and C- Haanen 
submitted for publication in the Journal of Chromatography 
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ABSTRACT 
A method is described for the determination of cytosine arabinoside 
triphosphate (ara-CTP) in cell extracts. Extraction of the intracellular 
ara-CTP is performed by addition of 250-500 yl of 50% ethanol in buffered 
saline to 2-4 χ 10 leukemic cells. An anion-exchange column (Partisi! SAX) 
is used for isocratic separation of ara-CTP from other nucleotides. The 
injection volume is 100 μΐ. Elution is performed with 0.125 M potassium-
dihydrogen-phosphate and 0.075 M tri sodium-ci trate, pH 4.6. Detection is 
carried out simultaneously at 280 nm and at 254 nm. Peak heights at 280 nm are 
used for quantification of the assay. Ratios of the absorbance at 280 nm and 
254 nm are used for purity-control of the peaks. In biological samples the 
lowest detectable amount of ara-CTP is 20 pmol. The variation coefficient of 
the whole procedure ranges from 3 to 11%. 
Accumulation of ara-CTP in peripheral leukemic blasts has been measured in 
3 patients after administration of cytosine arabinoside. Intracellular ara-CTP 
increases linearly during constant-rate infusion. Elimination of ara-CTP 
shows first-order kinetics. Phosphorylation of ara-C both in vivo and in vitro 
are essentially not different. 
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INTRODUCTION 
Cytosine arabinoside (ara-C, 1-ß-D-arabinofuranosylcytosine) is a cytostat ic 
drug, ef fect ive in the treatment of acute leukemia [ 1 , 2 ] . In vivo ara-C is 
deaminated rapidly to the inactive metabolite uraci l arabinoside (ara-U, 1-0-
D-arabinofuranosyluraci l)[3]. In the leukemic ce l ls ara-C isphosphorylated to 
cytosine arabinoside triphosphate (ara-CTP)[4, 5, chapter 5 ] , a metabolite 
in ter fer ing with the DNA synthesis [5 , 6, chapter 6 ] . The extend of ara-C 
phosphorylation is one of the main determinants for i t s cytocidal property 
[7 , 8 ] . Decreased phosphorylation of ara-C is associated with drug resistance 
in human and animal tumors [7 , 9, 10, 11, 12, 13, 14, chapter 5 ] . 
Hitherto, phosphorylation of ara-C has been studied by means of radio-
act ively labeled drug. Consequently, the investigations were l imi ted to in 
v i t ro experiments [ 1 1 , 12, 14, chapter 5 ] . Since a method for determination of 
small amounts of non-labeled ara-CTP was not avai lable, data concerning i n t r a -
ce l lu lar amounts of ara-CTP in vivo are lacking. 
Recently methods have been developed for ara-CTP determination by means of 
high pressure l i qu id chromatography (HPLC) [15, 16]. However, gradient e lut ion 
and laborious sample preparation make them time consuming. 
In th is chapter a simple method for cel l extract ion in combination with a 
rapid and sensit ive HPLC procedure, using isocrat ic e lu t i on , is described. The 
method is i l l us t ra ted by data obtained in three patients treated with ara-C. 
MATERIALS AND METHODS 
Patbents 
Measurements are performed in 3 pat ients, suffer ing from acute myeloid 
leukemia. Ara-C (200 mg/m body surface) is administered ei ther as bolus-
in ject ion (n=l) or as constant rate infusion of 1 hour (n=2) or б hours ( n = l ) . 
At several time intervals blood samples are taken for the determination of the 
ara-C plasmaconcentration and the quant i f icat ion of ara-CTP accumulated in 
the leukemic c e l l s . 
Ara-C phosphorylation by the leukemic cel ls is also measured in v i t r o . 
These data are compared with those measured in vivo. 
Detevrmnatbon of the ara-C conoentratton ъп plasma 
After deprotei m z a t i o n , the plasma samples are analysed by reversed-phase 
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high pressure liquid chromatography as described previously [17, chapter 2]. 
DeЬегтіпаЬъоп of th.p intracellular ara-CTF 
Pr§BËr§îl9D-9f.Ç§ii_§ïïrÈ£Î§· Blood (or bone marrow) samples are collected 
in ice-cold buffered acid citrate dextrose solution (ACD formula A, pH 7.4), 
and immediately placed on ice. Cells are washed once with ACD to prevent fibrin 
7 8 formation, and 10 to 10 nucleated cells are layered on a Percoli density 
cushion (d=1.080 g/ml ), and centrifugated for 20 m m , 800 g at 40C to remove 
erythrocytes. The cells are collected from the interface and washed in ice-
cold ACD. Cell-counting is performed with a Coulter Counter. Pelletation of 
2 to 4 χ 10 cells is performed by centri fugati on (10 min, 800 g, 4 0C). To the 
cellpellet 250 to 500 μΐ ice-cold ethanol/elution buffer (1/1, v/v) is added 
and total extraction of the intracellular nucleotides is achieved in 15 m m 
at 0 С Precipitated protein is removed from the extract by centrifugation 
(4 min, 3000 g, 0 oC). Of these extracts, 100 yl is used for analysis. 
ЬВУС_§9У19!Г§0£· Л Pye Umcam LC-3-XP pump, equipped with an automatic 
injection valve (Valco Houston AH 60), a 100 μΐ loop, and a column (259 χ 4.6 
mm i.d., Whatman Ltd) packed with Partisil-10-SAX amon-exchange resin is 
used for separation of the nucleotides. A guard column (30 χ 4.6 mm i.d., 
Partisil-10-SAX) is incorporated in the system to protect the analytical 
column. Two UV detectors are used: an UV III monitor LDC 1203 (10 μΐ flowcell, 
wavelength 280 nm) and a Pye Umcam LC-UV (8 μΐ flowcell .wavelength 254 nm). 
bELÇ.BroÇÇdure. Samples of 100 μΐ cell extract are injected into the column. 
Elution is carried out at a constant temperature (350C) and at a constant flow 
of 2.5 ml/min with a 0.125 M potassium-dihydrogen-phosphate solution, 
containing 0.075 M tri sodium-ci trate as counter-ion, adjusted to pH 4.6 (at 
35 С) with phosphoric acid. Helium gas is led through the eluent to prevent 
development of air-bubbles at the low pressure side. Detection of ara-CTP is 
optimal at 280 nm. Peak-heights are used for quantitation, whereas ratios of 
the absorbance at 280 nm and at 254 nm are used for purity control of the 
peaks. 
Determination of the phosphorylating capacity of the leukemia cells in vitro 
The leukemic cells are incubated during 30 min at 370C with different 
3 
concentrations H-ara-C. Then, the intracellular radioactive compounds are 
extracted with ethanol/water solution (1/1, v/v) and separated on PEI-
cellulose thin-layer plates (eluent 0.2 M ammoniumsulphate). The radioactivity 
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retention cime (min) 
Fig la. Chromatogram of a mixture of nucleotides. Detection at 280 nm. 
Conditions: see under Methods. 
l=mono- and diphosphates, 2=uridine triphosphate, 3=deoxycytidine triphosphate, 
cytidine triphosphate and deoxythymidine triphosphate, 4=arabinoside cytosine 
triphosphate, 5=adenosine triphosphate, 6=deoxyadenosine triphosphate, 7= 
guanosine triphosphate, 8=deoxyguanosine triphosphate. 
Fig lb. Chromatogram of extract of leukemic cells, incubated with 10 μΜ ara-C 
in vitro. Detection at 280 nm, 0.004 a.u.f.s. 
Arrow indicates ara-CTP peak. 
present in the ara-CTP fraction is counted with a liquid scintillation counter. 
The phosphorylation of ara-C is characterized by calculating the maximal 
ara-CTP formation in 30 min (V
m a x
) and an equivalent of the Michaelis-Menten 
constant (1^). This method is described in detail in chapter 5. 
RESULTS 
Determination of ara-CTP by HPLC 
Separation of ara-CTP from natural ly occuring analogues is achieved wi th in 
17 min (Fig l a ) . A chromatogram of a leukemic c e l l extract is shown in Fig l b . 
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Fig 2a. Calibration curve of the extraction of increasing cell numbers. 
Cells are incubated with ara-C in vitro and extracted with 500 μΐ extraction 
solution. Chromatographic conditions: see under Methods. 
Fig 2b. Calibration curve of the determination of ara-CTP, including the 
extraction procedure. Leukemic cells, incubated with ara-C in vitro, are mixed 
with non-incubated leukemic cells in varying ratios. 
Leukemic cell extracts never contain compounds which interfere with the 
ara-CTP peak, as can be checked by the 280/254 nm ratio. The lowest detectable 
amount in biological samples is 20 pmol. The calibration curve is linear over 
3 decades and passes through the origin. The coefficient of variation ranges 
from 3% (1 nmol, n=6) to 11% (50 pmol, n=6). 
Extraction procedure 
Up to 5 χ 10 cel ls can be extracted quant i tat ive ly with 500 μΐ extract ion 
solut ion (Fig 2a). To prove l i n e a r i t y of the c a l i b r a t i o n curve, including the 
extract ion procedure, leukemic cel ls incubated in v i t r o with ara-C are mixed 
with non-incubated cel ls in d i f ferent proportions before extract ion. This 
ca l ibrat ion curve is also l inear and passes through the or ig in (Fig 2b). 
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Fig 3. Accumulation of ara-CTP in leukemic cells of peripheral blood during 
constant rate infusion of ara-C. 
(a) constant rate infusion of 200 mg/m2 ara-C in 1 hr (patient 1) 
(b) constant rate infusion of 200 mg/m2 ara-C in 1 hr (patient 2) 
(c) constant rate infusion of 200 mg/m2 ara-C in 6 hr (patient 1) 
Determination of ara-CTP ir. leukeric cells in vivo after ara-C adr.inistration 
Fifteen minutes after starting ara-C admini strati on .ara-CTP is detectable 
in the leukemic cells. 
During constant rate infusion of ara-C, intracellular ara-CTP shows an 
almost linear increase (Fig 3). Maximal values range from 9 to 16 pmol/10 
cells. The intracellular amount of ara-CTP decreases shortly after termination 
of ara-C infusion. 
After the intravenous bolus injection intracellular ara-CTP increases 
during 30 minutes (maximal value 7 pmol/10 cells; Fig 4a). 
Ara-CTP is eliminated with first order kinetics (half-life times 60 and 
120 min; Fig 4a and 4b). 
Comparison of phosphorylation of ara-C in vitro and in vivo 
The values of К -equivalent and V
m
 . calculated from the in vitro 
III ΓΠαΧ 
incubation studies, are given in table 1. On the basis of the given data it is 
possible to estimate the amount of ara-CTP accumulated at an ara-C 
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Fig 4. Time curves of ara-C plasmaconcentration (· ·) and of amount of 
ara-CTP in leukemic cells ( o — o ) after administration of 200 mg/m2 ara-C 
as bolus injection (Fig 4a) and as constant rate infusion of 1 hr (Fig 4b). 
concentration, comparable with the plasmaconcentration achieved during 
infusion. The expected ara-CTP accumulation agrees well with the accumulation 
observed in vivo after 1 hr infusion (table 1). Considering the rapidly 
changing ara-C plasmaconcentration, a prognostication of the amount of ara-CTP 
accumulated after a bolus injection,is very difficult and requires computer 
simulation. 
The half-life times of ara-CTP, observed in vitro and in vivo, are also 
similar (table 1). 
DISCUSSION 
The method for the determination of ara-CTP in leukemic cells as described 
in this chapter, is simple, rapid, and sensitive. 
Employing this assay it is demonstrated, that ara-C bolus injection results 
in maximal ara-CTP levels about 30 min after administration, whereas ara-CTP 
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TABLE 1 
COMPARISON OF IN VITRO DATA FOR FORMATION AND DEPH05PHORYLATION OF ARA-CTP WITH THOSE IN VIVO 
P a t i e n t 
1 
1 
2 
3 
Ara-С 
Dose 
(mg/m 
200 
200 
200 
200 
a d m i n i s t r a t i o n 
Mode 
2 ) 
1 h r i n f u s i o n 
6 hrs i n f u s i o n 
1 hr i n f u s i o n 
b o l u s i n j e c t i o n 
Ara-CTP format 
ЬУ vztro 
'S» 
(UM) 
4.2 
4.2 
5 9 
10.9 
V· 
max 
22 
22 
23 
37 
i o n 
m VZJO 
Ara-CTP 
p r e d i c t e d » * 
15.0 
4 . 1 
15.7 
-
Ara-CTP 
o b s e r v e d * * * 
16.0 
2.8 
12.7 
5.2 
Ara-CTP di 
in vitro 
( m m ) 
75 
75 
-
117 
e p h o s p h o r y l a t i o n 
zn г о 
(min) 
60 
-
-
120 
* "max·
 m a x l m a l amount of ara-CTP (pmol/10 cells) formed after 30 m m incubation with ara-C 
** Predicted amount of ara-CTP (pmol/lO cells) at 60 m m after initiation of infusion, calculated 
from K , V_.„, and plasma concentration of ara-C m max K r 
*** Amount of ara-CTP (pmol/10 cells) observed at 60 m m after initiation of infusion or bolus 
injection 
1^, equivalent of Michaelis-Menten constant of ara-C phosphorylation (see Chapter 5) 
T,, half-life time 
increases linearly during constant rate infusion. 
Phosphorylation in vivo and in vitro seems to be similar. Although ara-C 
plasmaconcentrations are considerably higher shortly after bolus injection 
than during constant rate infusion of the same dose, the initial accumulation 
rate of ara-CTP after injection does not surpass the accumulation rate during 
infusion (Fig 4). Saturation of the phosphorylation may account for this 
phenomenon. Therefore, short infusions may produce higher intracellular 
ara-CTP levels than bolus injections of the same dose. 
Elimination of intracellular ara-CTP in vivo shows first order kinetics. 
The half-life times observed correlate very well with those in vitro. 
Pharmacokinetic studies are performed generally to relate variations in 
pharmacokinetic parameters to individual therapeutic or toxic effects [18, 19]. 
In all previous pharmacokinetic studies about ara-C only plasmaconcentrations 
are considered. A correlation between the half-life time of ara-C and the 
therapeutic response has been reported [20, 21], but this has not been con­
firmed by others [22]. Since the active compound is not ara-C but the intra­
cellular metabolite ara-CTP, variations in the therapeutic efficacy may be 
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related more closely to differences in the pharmacokinetics of ara-CTP. 
This hypothesis is supported by the notorious wide variation in the 
phosphorylatmg activity of leukemic cells (chapter 5). The clinical relevance 
of the pharmacokinetics of ara-C and of its active metabolite ara-CTP can be 
studied by means of the described assays. 
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ABSTRACT 
The perturbation of the proliferative activity of leukemic cells has been 
measured in 11 patients with acute myeloid leukemia after intravenous bolus 
2 
injections ara-C (100, 380 and 1000 mg/m ). The proliferative activity of 
leukemic cells derived from bone marrow and peripheral blood, has been 
determined by means of Η-thymidine autoradiography (labeling index), 
r> 
DNA-flowcytometry, and Η-thymidine incorporation. Data obtained from bone 
marrow aspirates are corrected for peripheral blood admixture. Before ara-C 
administration, the three methods used correlate very well. 
After ara-C injection, each method shows a specific pattern. Labeling 
indices regain pretreatment levels at Z4 hours, after an initial decrease. 
The percentage cells with > 2n<4n DNA as determined by DNA-flowcytometry 
shows only a slight decrease, followed by a significant increase with maximal 
values at about 30 hours after injection. The discrepancy between labeling 
indices and DNA-flowcytometric data may be due to the presence of cells 
3 
arrested in S-phase. Η-thymidine incorporation increases to twice pretreat­
ment values after about 30 hours. Recruitment is not demonstrated. The 
observations suggest partial synchronization. 
3 
Incorporation of Η-thymidine in peripheral nucleated cells correlates well 
3 
with H-thymidine incorporation in bone marrow cells. 
No difference is observed between the three dosages. 
The observations indicate that 24 hourly scheduling may be optimal for 
ara-C given by bolus injection. 
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INTRODUCTION 
In the treatment of acute myeloid leukemia (AML) cytosine arabinoside 
(ara-C, 1-ß-D-arabinofuranosylcytosine) is one of the major chemotherapeutic 
agents [1, 2]. Its cytostatic activity is based on the inhibition of DNA 
synthesis by competitive interference of the intracellular metabolite cytosine 
arabinoside triphosphate (ara-CTP) with deoxycytidine triphosphate for the 
enzyme DNA-polymerase [3, 4, 5, 6]. 
The inhibition of cellular DNA synthesis, caused by intravenous 
administration of ara-C, differs considerably in leukemic patients [6, 7, 8]. 
This may be related to individual differences in the pharmacokinetics of ara-C 
[6, 7, 9], to differences in the phosphorylating capacity of the leukemic cells 
[3, 10, chapters 5 and 7], or to differences in the sensitivity of the DNA-
synthesis [8, 11, 12, 13, chapter 6]. The antileukemic effect of a treatment-
course also depends on the dose and spacing of ara-C administration, on the 
number of injections, and on the percentage of cells in S-phase at the moment 
of injection [14, 15]. 
In animal models high dosages of ara-C cause accumulation of cells in S-
phase and treatment results are substantially improved when subsequent 
injections are given at the moment of maximal S-phase accumulation [16, 17, 18, 
19, 20]. Schedules used in human AML are almost completely empirical. Adjust-
ment of administration intervals till the moment of maximal S-phase accumulation 
may improve treatment results in human AML as well. 
This paper reports the results of a study in which cytokinetic changes are 
investigated in bone marrow and peripheral blood of patients with AML after 
intravenous bolus injections of different ara-C-dosage. 
MATERIALS AND METHODS 
Patie η ta 
Cell-kinetic studies are performed in 11 patients with AML before and at 
different time intervals after an intravenous bolus injection of ara-C. 
Clinical data at the time of investigation are summarized in table 1. Only one 
patient received previous cytostatic treatment. One intravenous bolus-injection 
2 2 
of ara-C, respectively 1000 mg/m body surface (3 patients), 380 mg/m (4 pa-
2 
tients) or 100 mg/m (4 patients) is given to each patient. 
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TABLE 1 
HEMATOLOGICAL DATA OF PATIENTS 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Age 
(years) 
53 
60 
31 
68 
53 
41 
40 
40 
34 
24 
44 
Sex 
m 
f 
f 
m 
m 
m 
f 
m 
m 
f 
m 
Morphological 
diagnosis* 
M 1 
M 4 
M 4 
M 2 
M 1 
M 1 
M 2 
M 1 
M 1 
M 1 
M 2 
WBC** 
(x 109/1) 
75 
6 
50 
66 
71 
127 
16 
96 
8 
16 
26 
% blasts in 
peripheral blood 
70 
1 
69 
32 
89 
69 
17 
83 
25 
60 
30 
% blasts in 
bone marrow 
73 
50*** 
88 
90 
74 
93 
45**** 
95 
90 
71 
70 
* Classification according to the French-American-British (FAB) Co-operative Group 
classification (Ref. 22) 
** WBC, white blood cell count 
*** Remainder are pathological (proMyelocytes 
**** Bone marrow contains 17% erythropoiesis 
Samp ling 
Bone marrow aspirates and peripheral blood samples are collected in buffered 
acid citrate dextrose solution (ACD formula A, pH 7.4). For technical reasons, 
in one patient (no. 11) only peripheral blood has been monitored. Cells are 
washed in order to prevent fibrin formation during incubation. Erythrocytes 
are not removed from the samples, since they do not interfere with the 
measurements. 
Determination of the labeling index 
3 
To 100 μΐ of blood or bone marrow sample, 0.5 pCi Η-thymidine (Radio­
chemical Centre Amersham, specific activity 5 Ci/mmol) is added. After 
incubation for 60 min at 37 C, smears are prepared, air-dried, fixed in 
methanol, and stained with May-Grünwald-Giemsa. The slides are covered with 
polyvinylidenechloride to prevent chemography of the overlayered Ilford L 4 
photographic emulsion [22]. Autoradiographs are examined after an exposure of 
14 days at 4 С The percentage labeled cells is determined by counting at 
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least 2000 nucleated cells. Cells with more than 5 grains are considered to be 
labeled. 
Détermination of cellular DNA contení, uith f lew су tome try 
The nuclear DNA of about 10 cells of each blood or bone marrow sample is 
stained by adding a small volume of the cellsuspension to 10 ml hypotonic 
ethidium bromide solution (0.1% tri-sodium citrate, 25 mg/1 ethidium bromide) 
ς 
according to Krishan [23]. The relative fluorescence of about 10 individual 
cells is measured in a flowcytometer (ICP-11, Phywé). To determine the per-
centage of cells containing >2n<4n DNA, the histograms are analysed according 
to Göhde [24] with a computer program described by van Egmond et al [25]. 
з Determination of the h-thymidine incorporation 
Blood and bone marrow samples are diluted in medium 199 (Flow Laboratories) 
buffered with 10 mM Tris (pH 7.4) and supplemented by 10% heat inactivated 
fetal calf serum (Flow Laboratories) to a final cell concentration of 10 
3 
nucleated cells per ml. Four aliquots of 1 ml are incubated with 2 yCi H-
thymidine (specific activity 5 Ci /mmol) for 60 min at 37 С. The incubation is 
stopped by addition of 2 ml ice-cold medium with an excess of unlabeled 
thymidine. The cells are collected on glass fibre filters (Schleicher and 
Schuil no. 9), washed and lysed with water, and precipitated with 1 M 
perchloric acid [26]. The total amount of radioactivity in the perchloric acid 
precipitated fraction is counted in a liquid scintillation counter (LKB 81000) 
with a counting efficiency of about 30%. 
Correction for peripheral blood admixture and error analysis 
The fraction of contaminating peripheral nucleated cells, present in the 
bone marrow aspirates, is calculated according to Holdrinet et al [27]. This 
method is based on the observation that almost all red cells present in a 
bone marrow sample are derived from peripheral blood admixture. Determination 
of hemoglobin content and the number of nucleated cells in the blood and bone 
marrow sample allows the calculation of the fraction of nucleated cells in the 
aspirate originating from the bone marrow compartment (F. ) according to the 
formula: 
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N C
n h Hb:, pb a 
F. = 1 x 
bm NC, Hb. 
a pb 
NC . , NC : nucleated cell count in peripheral blood, aspirate 
Hb , , Hb : hemoglobin content in peripheral blood, aspirate 
The cellkinetic data (D) of the bone marrow compartment are calculated from 
the measurements on both the aspirate and the peripheral blood, according to: 
D
a - ( ! - Fbm ) Dpb 
Dbm - — 
bm 
3 
D : labeling index, percentage cells with > 2n < 4n DNA or H-thymidine 
incorporation 
The error in F. is a function of the individual errors of cell counts and 
hemoglobin measurements in bone marrow aspirate and peripheral blood and can 
be calculated with the formula [28] : 
ΔΟ 
-/{(*, «if 
3D/3x. : first derivative to the i-th variable 
Δχ. : standard error of the i-th variable 
D : any parameter to be calculated from the variables 
RESULTS 
Peripheral blood admixture in bone marrow aspirates 
The fraction of peripheral nucleated cells in the bone marrow aspirates 
varies considerably, even within the same patient (Fig 1). Four aspirates 
contain more than 50% peripheral nucleated cells. Since the relative error 
on the Fu exceeds 10% in these cases, these samples are excluded from further 
evaluation. 
Accuracy of data 
Errors on all data are calculated as described under methods. For labeling 
indices over 6% the relative error is about 15%. Flowcytometric determination 
of the percentage S-phase cells is more accurate: for values over 4%, the 
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α> 100 -
patient 
Fig 1. Fraction of nucleated cells in bone marrow aspirates originating from 
the bone marrow compartment (F. ). 
3 
relative error is less than 10%. The relative error of the H-thymidme 
incorporation is less than 10% for values over 1000 cpm/10 cells. For data 
below these limits the relative errors increase rapidly. 
Bone marrow S-phase compartment before treatment 
The relative number of proliferating cells before ara-C injection differs 
in patients. The percentage S-phase cells, determined by labelmgindices varies 
from 3.4 to 20.5%. The S-phase compartment, as determined by DNA-flowcytometry, 
ranges from 4.7 to 21.6%. Correlation between these methods is good (correlation 
coefficient 0.93). In one patient (no 9) the number of S-phase cells could not 
be calculated from the DNA-histograms for reason of a polyploidy. Incorporation 
of H-thynndine ranges from 4400 to 59700 cpm/10 cells. For all patients, 
3 
except patient 2, H-thymidine incorporation correlates with the labelingmdex 
(correlation coefficient 0.87, patient 2 omitted) and with flowcytometry 
(correlation coefficient 0.93, patient 2 omitted). 
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TABLE 2 
CHANGES IN LABELING INDEX IN BONE MARROW CELLS AFTER ARA-C ADMINISTRATION 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
IO 
11 
Ara-C dose 
(mg/пГ) 
1000 
1000 
1000 
380 
380 
380 
380 
100 
100 
100 
100 
Hours 
0 
12.0 
20.5 
6.8 
3.4 
18.1 
13.4 
8.2 
19.0 
3.9 
12.4 
after 
1 
1. 
0 
ara-C 
0 
administration* 
7 
0.9 
4.0 
1.6 
0 
2.5 
5.2 
1.3 
*« 
0 
3.9 
23 
8.1 
3.0 
12.2 
t« 
8.7 
16.9 
6.1 
12.2 
31 
11.7 
13.4 
16.4 
3.4 
** 
13.2 
6.0 
17.2 
** 
9.5 
47 
14.2 
12.0 
13.9 
3.3 
13.7 
16.2 
6.7 
70 
6.4 
'Values indicate % labeled cells (labeling index) 
»•Aspirate contains more than S0% peripheral nucleated cells 
TABLE 3 
CHANGES IN PERCENTAGE BONE MARROW CELLS WITH > 2n<4n DNA AFTER ARA-C ADMINISTRATION 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Ara-C dose 
(mg/ra2) 
1000 
1000 
1000 
380 
380 
380 
380 
100 
100 
100 
100 
Hours 
0 
11.0 
21.6 
9.8 
4.7 
14.3 
14.7 
9.2 
17.4 
polypi 
11.4 
after 
1 
16 
oidy 
ara-C 
.3 
administration* 
7 
7.3 
19.2 
4.5 
4.0 
10.3 
6.1 
9.4 
** 
7.8 
23 
10.0 
6.7 
17.7 
Φ* 
13.3 
18.0 
14.7 
31 
11.1 
27.2 
14.0 
8.3 
** 
19.3 
13.6 
23.8 
16.0 
47 
17.9 
18.2 
12.3 
6.8 
16.4 
19.1 
10.5 
70 
7.1 
•Values indicate % bone marrow cells with > 2n<4n DNA 
•»Aspirate contains more than 50% peripheral nucleated cells 
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TABLE 4 
CHANGES IN V T H Y M I D I N E INCORPORATION IN BONE HARROW CELLS AFTER ARA-C ADMINISTRATION 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Ara-C dose 
(mg/m ) 
1000 
1000 
1000 
380 
380 
380 
380 
100 
100 
100 
100 
Hours i 
0 
16867 
59745 
11027 
4436 
14343 
19735 
10772 
24957 
6230 
18Э00 
after ara-C 
1 
534 
1503 
administration* 
7 
7405 
8275 
2033 
1195 
2057 
4746 
4495 
** 
1038 
7613 
23 
25776 
3917 
15329 
** 
14764 
17667 
20358 
19125 
31 
41116 
20759 
17337 
··* 
»* 
35512 
19315 
44019 
«* 
8119 
47 
42428 
17775 
14467 
3985 
26338 
31769 
12325 
70 
8818 
»Values indicate Η-thymidine incorporation (cpm/10 cells) 
»»Aspirate contains more than 50% peripheral nucleated cells 
•»»Contamination with bacteria 
Perturbation in S-phase compartment of bone marrow cells after ara-C injection 
Changes in labeling index. Labeling indices, determined 7 hr after ara-C 
administration, are significantly below pretreatment levels in all évaluable 
patients. The data found 23 hr after injection are comparable with pretreatment 
values. Labeling indices obtained after ara-C administration do not exceed 
significantly pretreatment values except for patient 3. Data are summarized in 
table 2. 
Changes in DNA-flowcytometric data. Generally a slight decline in the per-
centage S-phase cells is observed 7 hr after ara-C injection (table 3). After 
23 hr, in 5 out of 7 évaluable patients values have returned to pretreatment 
levels and show a further increase afterwards. In all 8 patients, évaluable 
31 hr after injection, the percentage S-phase cells exceeds significantly pre-
treatment values and tends to decline later on. 
3 3 
Changes in Η-thymidine incorporation, (table 4). Η-thymidine incorporation 
is significantly decreased 1 and 7 hr after ara-C administration. The incorpo­
ration measured 23 hr after injection is comparable with the incorporation 
before ara-C administration. Thereafter, a marked increase is observed in most 
patients. In 7 out of 10 patients maximal values obtained surpass pretreatment 
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TABLE 5 
CHANGES IN 3H-THYMIDINE INCORPORATION IN PERIPHERAL BLOOD CELLS AFTER ARA-C ADMINISTRATION 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Ara-C dose 
(mg/m2) 
1000 
1000 
1000 
380 
380 
380 
380 
100 
100 
100 
100 
Hours 
0 
565 
6496 
1490 
676 
554 
8708 
3741 
5378 
1982 
370 
2699 
after 
1 
259 
279 
955 
ara-C administration* 
7 
281 
909 
878 
473 
340 
4057 
1472 
569 
910 
2045 
12 
657 
3083 
23 
848 
1456 
837 
11272 
5125 
3596 
3936 
2935 
27 
4823 
1604 
31 
953 
1996 
2185 
*** 
1397 
10922 
7125 
6403 
1640 
47 
1054 
1626 
1836 
1078 
1283 
6509 
5535 
2294 
70 
1118 
r** 
0 97 
0 99 
0 96 
0 81 
0 96 
0 89 
0 98 
0 96 
0 98 
* Values indicate Η-thymidine incorporation (cpm/lO cel ls) 
** Correlation coefficient of 5H-thymidine incorporation in bone marrow and peripheral blood 
*** Contamination with bacteria 
values (1.5 to 2.5 times higher). In patient 4 the elevation may be missed as 
the 31 hr sample could not be analysed. In patient 2 thymidine incorporation 
does not return to pretreatment level . In th is case thymidine incorporation 
before ara-C administration is extremely high and not proportional to the per­
centage of S-phase c e l l s . In patient 10 only a s l i g h t increase is observed. 
СуЬокгпеЬго measurements гп peripheral blood 
As the percentage of p r o l i f e r a t i n g cel ls in peripheral blood is mostly very 
low, r e l a t i v e errors in labeling indices and DNA-flowcytometnc data are too 
3 
high in order to perform accurate measurements. H-thymidine incorporation is 
a more sensit ive parameter and in 10 out of 11 patients i t appears high enough 
3 
to produce évaluable resu l ts . Only in one patient (no 10) H-thymidine incor-
poration is too low for evaluation (less than 500 cpm/10 ce l l s ) . Thymidine 
incorporation in peripheral blood cel ls shows in a l l patients the same pattern 
as in bone marrow at a lower leve l . Correlation coeff ic ients of the thymidine 
incorporation in bone marrow and peripheral blood in individual patients range 
from 0.81 to 0 99 (table 5) . 
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Effect of the dosage of ara-C 
The perturbation of the cell cycle, produced by the three different dosages 
2 2 2 
ara-C (100 mg/m , 380 mg/tn and 1000 mg/m ) displays no essential differences. 
DISCUSSION 
As has been shown recently by Holdrinet [29] and also in this study, the 
percentage of nucleated cells derived from the peripheral blood in a bone 
marrow aspirate varies considerable. To our knowledge this contamination never 
has been taken into account in cellkinetic studies performed with bone marrow 
aspirates. This factor may be responsible for the fluctuations, reported in 
previous studies about cellkinetic changes after cytostatic therapy [30, 31, 
32, 33]. After elimination of the influence of peripheral blood admixture, the 
cytokinetic perturbation of the bone marrow blasts shows good similarity in all 
patients. Furthermore, the correction procedure unmasks a good correlation 
3 
between Η-thymidine incorporation in bone marrow cells and in peripheral 
nucleated cells. 
No studies are available which compare the results of autoradiography, DNA-
3 
flowcytometry and Η-thymidine incorporation of leukemic cells before and 
during 48 hours after ara-C administration. Before ara-C injection a good cor­
relation exists between the three methods. After ara-C administration the cor­
relation appears to be disturbed. The differences between the patterns ob­
tained with each method provide additional information about the cytokinetic 
effects of ara-C. 
After an initial decrease, labeling indices return to pretreatment values. 
A pronounced increase in the labeling index as described in animal models [19] 
is not observed. Our data confirm the findings of Ernst et al [30] and Lange 
Wantzinetal [33]. Lampkin et al [32] found a significant increase of the 
labeling index in half of the patients 18 to 24 hours after ara-C administra­
tion. This observation may be caused by a variable amount of peripheral blood 
admixture in the bone marrow samples. 
The decrease in the percentage S-phase cells, measured with DNA-flowcyto-
metry, is less pronounced than that estimated from labeling indices. Maximal 
values found with flowcytometry are about 1.5 times pretreatment values. The 
discrepancy between labeling indices and flowcytometric data may be explained 
3 
by the presence of cells arrested in S-phase. The reduction in the H-thymidine 
incorporation after ara-C injection is proportional to the decrease in the 
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labeling indices. Pretreatment levels are reached after about 24 hours, 
followed by a further rise to maxima of about double pretreatment values. 
Since the labeling indices do not increase significantly, the increased 
thymidine incorporation may be due, for instance, to partial synchronization 
of cells in mid-S-phase [34, 35]. 
In conclusion, changes suggesting recruitment of leukemic cells by ara-C 
have not been observed; the data are suggestive for the occurrence of partial 
synchronization; evidence is obtained for the presence of cells arrested in 
S-phase after ara-C injection. 
Thymidine incorporation in peripheral blood cells shows a close correlation 
with data of the corresponding bone marrow (table 5). Therefore, incorporation 
studies in peripheral blood may be a more suitable method for monitoring the 
cellkinetic response in individual patients after ara-C injection. 
No essential differences in the perturbation of the cell cycle have been 
observed with respect to the three different dosages, albeit that a dose of 
2 
100 mg/m ara-C may not always be sufficient to produce the required inhibition 
of the DNA synthesis [6] and to damage S-phase cells irreversibly. The early 
increase of the thymidine incorporation in patient 11 may be due to such a 
phenomenon. 
In almost all patients the relative size of the S-phase compartment return 
to pretreatment levels about 24 hours after ara-C administration. Hence, 
treatment schedules with intervals of 24 hours will probably result in more 
effective elimination of the leukemic cells in comparison to schedules with 
shorter intervals. 
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ABSTRACT 
Sixteen patients with relapsed, refractory or bad-risk acute myeloid 
2 2 
leukemia have been treated with daily injections of 200 mg/m (n=5)) 300 mg/m 
2 (n=2), or 500 mg/m (n=9) cytosine arabinoside (ara-C) for 7 to 14 days. 
An additional injection with an anthracycline derivative has been administered 
to 9 patients. 
Fourteen patients were évaluable, of whom 5 attained complete remission. 
Toxicity of the treatment was acceptable. The most life-threatening side-
effect is bone marrow depression, lasting about 14 days after the treatment 
course. Eye toxicity, a side-effect recently described for the first time, 
was observed in 5 out of 8 patients treated with injections of 500 mg/m ara-C. 
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INTRODUCTION 
The introduction of cytosine arabinoside (ara-C, 1-ß-D-arabinofuranosyl-
cytosine) in the therapy of acute myeloid leukemia (AML) markedly improved 
treatment results. With induction schemes containing ara-C complete remissions 
are achieved in up to 80% of previously untreated patients [1, 2, 3, 4, 5]. In 
most cases more than one treatment course is necessary to accomplish apparent 
complete remission, which implicates several periods of aplasia with 
concomitant risk of hemorrhage and infection. Optimalization of dosage and 
scheduling may lead to more effective leukemic cell-kill and it may shorten 
the aplastic time period. 
2 
The most frequently used dose for ara-C injections is 100 mg/m body 
surface [3, 4, 5]. Due to rapid deamination of ara-C to the inactive metabolite 
uracil arabinoside (ara-U, l-3-D-arabinofuranosyluracil)[6], the ara-C con-
centration required for complete inhibition of the DMA synthesis in the 
leukemic cells [7, chapter 6] may not be maintained long enough. Relatively 
resistent cells may therefore escape from elimination, leading to diminished 
efficacy of the treatment and to selection of resistent leukemic cells [8, 9]. 
This can be avoided by administration of higher dosages. High dosages of ara-C 
are tolerated rather well when given as a limited number of injections or as 
short constant rate infusions [10, 11]. 
Since ara-C is a S-phase-specific agent [6, 12, 13, 14], leukemic cell kill 
is correlated with the percentage of cells in the susceptible phase [12, 13, 
14, 15]. In animal leukemias, treatment results improved by spacing of sub-
sequent injections at the moment of maximal S-phase activity [12, 16]. In 
earlier studies we showed that in human acute myeloid leukemia the percentage 
S-phase cells regains the initial value not earlier than 24 hours after 
administration of higher dosages ara-C [17, chapter 9]. To eradicate the 
leukemic cell-population with a minimal load of ara-C, intervals of 24 hours 
may be more appropriate. 
To evaluate the therapeutic and toxic effects of longer-lasting treatment 
with ara-C injections of increased dose, 16 patients with relapsed or refractory 
acute myeloid leukemia have been treated with daily bolus-injections of 200 to 
500 mg/m2 for 7 to 14 days. 
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TABLE 1 
CHARACTERISTICS OF PATIENTS, DETAILS ABOUT TREATMENT, AND TREATMENT RESULTS 
Patient 
1 
2 
3 
4 
S 
6 
7 
θ 
9 
IO 
11 
12 
13 
14 
15 
16 
Age Sex 
(years) 
53 
20 
24 
38 
63 
34 
66 
28 
32 
18 
27 
37 
45 
42 
48 
33 
m 
m 
Diagnosis* 
M 1. 
M 1, 
M 5, 
M 2, 
Мб, 
M 1, 
M 2. 
M 2. 
M 4. 
M 2. 
M 4, 
M 1. 
M 2, 
M 2, 
M 2, 
M 4, 
RI, F(lam 5) 
R2 
RI 
ND·* 
ND·* 
ND, F(PVD) 
ND** 
R2 
R3 
RI, F(lam 5) 
R2 
ND, F(lam 5) 
ND, F(lam 5) 
RI 
R2 
ND, F(lam 5) 
R2 
Duration 
previous 
(months) 
14 
17 
7 
3 
0 
1 
6 
21 
24 
12 
22 
2 
1 
9 
21 
1 
36 
Of 
therapy 
Dosage 
Ara-C 
(mg/m2) 
200 
200 
200 
200 
200 
300 
300 
500 
500 
500 
500 
500 
500 
500 
500 
500 
500 
Number of 
injections 
14 
14 
14 
10 
7 
7 
10 
13 
13 
7 
14 
1 
10 
10 
10 
10 
9 
Anthracycline 
derivative 
-
+ 
-
+ 
-
-
-
+ 
+ 
-
-
-
+ 
+ 
+ 
+ 
+ 
Result*** 
CR 
F 
F 
F 
F 
CR 
F 
CR 
F 
NE 
A 
NE 
PR 
F 
CR 
NE 
CR 
Duration 
of effect 
(months) 
7 
-
-
-
-
10 
-
2 
-
-
-
-
3 
-
5 
-
5 
Survival 
after therapy 
(months) 
12 
4 
4 
3 
1 
13 
11 
5 
2 
0 
1 
0 
15 
3 
7 
0 
7 
•Acute myeloid leukemia (AML); classification according to the French-American-British (FAB) Co-operative Group Classification 
(Ref. 18), ND, newly diagnosed, Rl, R2, and R3, first, second, and third relapse; F(lam 5), failure of treatment according to 
the EORTC protocol lam 5, F(PVD), failure of treatment with prednisone, vincristine, and daunorubicme 
**Patients with previous preleukemic syndrome 
•**A, aplasia; CR, complete remission, F, failure, NE, not évaluable; PR, partial remission 
MATERIALS AND METHODS 
Patients 
Sixteen patients with acute myeloid leukemia (AML) entered the study 
(table 1). Three patients received this scheme as first-line treatment, because 
they were considered bad risk patients, having developed to AML after a 
preleukemic phase of more than 6 months. Three patients failed to standard 
initial induction chemotherapy, consisting of adriamycin, vincristine and 
ara-C (according to the LAM 5 protocol). One patient, initially diagnosed as 
acute undifferentiated leukemia, failed to prednisone, vincristine and dauno-
rubicin. Nine patients were treated with this scheme for relapsed disease. The 
total number of treatment courses was 17. 
None of the patients had liver or kidney function disturbances. In 13 
g 
patients the thrombocyte number was below 50 χ 10 /liter at the start of 
g 
therapy, and 11 patients were leukemic with leukocyte numbers > 15 χ 10 /liter. 
Treatment schedule 
Ara-C was administered for 7 to 14 days as intravenous bolus-injection with 
2 
intervals of 24 hours. In 5 patients a dose of 200 mg/m was given. Two 
2 
patients received 300 mg/m . Nine patients (10 courses) were treated with 
2 
dosages of 500 mg/m . One injection with an anthracycline derivative was added 
at the end of 9 treatment courses. These data are summarized in table 1. 
Supportive treatment (Packed cells, platelet-or leukocyte-concentrates, anti­
biotics etc.) was given when indicated. 
Criteria of response 
Patients were considered to be in çomglete^emission (C.R.) when the bone 
marrow was normocellular with less than 5% blastic cells and when the 
g 
peripheral blood contained more than 1 χ 10 /liter granulocytes and more than 
g 
100 χ 10 /liter thrombocytes. Partial remission (P.R.) was considered to be 
achieved if the bone marrow showed >50% reduction of blastic cells, with 
concomitant recovery of the peripheral blood counts as defined under C.R. 
Cy!I?ÌÌ9D_°f_9iB· was measured from the day that remission was documented to 
the day of first evidence of relapse. Survival was measured from the first day 
of intermediate-dose ara-C treatment to death. Ii'!)e_2eriod_of_bone_marrow 
degression was defined as the number of days between the last cytostatic 
injection and the first sign of recovery of the peripheral blood (granulocytes 
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and thrombocytes) or the reappearance of blastic cells in the peripheral blood. 
RESULTS 
Antileukemic effect of the treatment 
For each patient the effect of the treatment course is given in table 1. 
Three patients died during the treatment course or shortly thereafter (N.E.)· 
All were in bad condition with extended disease and high fever, before therapy 
started. One patient died without recurrent leukemia 3 weeks after the last 
injection, with a hypoplastic bone marrow. Of the other 13 treatment courses 
5 resulted in C.R., 1 in P.R. Seven patients failed to respond. No obvious 
difference was found between the different dosage schemes. 
Another parameter for the efficacy of the leukemic cell kill by a cytostatic 
regimen is the disappearance rate of the peripheral blasts [8, 19]. In 9 
patients the half-life times of the peripheral leukemic cells could be 
calculated and ranged from 29 to 94 hours (Fig 1). In 14 out of 16 évaluable 
treatment courses all blasts were eliminated from the peripheral blood. 
150 
100 
gi-
so -
Fig 1. Disappearance rate of peripheral blasts. 
A, bad-risk patients, treated with 200-500 mg/m¿ ara-C once a day 
B, patients with newly diagnosed AML, treated with 100 mg/m2 ara-C twice a 
day (van Prooi jen, Ref. 8). 
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TABLE 2 
SIDE EFFECTS OF ARA-C IN RELATION TO DOSAGE 
Dosage a ra -C 200-300 mg/m' 500 mg/m 
Donc marrou ¿lepre ¿,ΰΐοη 
nadir leukocyte count 
nadir thrombocyte count 
duration aplasia 
median 1.0 χ 1 0 / 1 
range 0 . 3 - 2.6 (n=7) 
median 7 χ 109/1 
range 5- 29 (n=7) 
median 12 days 
range 10- 25 (n=7) 
median 0.3 χ 1 0 / 1 
range 0 . 2 - 1.0 (n=7) 
median 8 χ lO^/l 
range 5 - 1 0 (n=7) 
median 15 days 
range 12- 20 (n=7) 
Gaatro-гпtentinal disturoances 
vomiting: no/s l ight 
moderate 
severe 
weight loss over 5% 
eye toxicity 
4 patients 
3 patients 
0 patients 
1 patient (n=7) 
0 patients (n=7) 
3 patients 
1 patient 
5 patients 
2 patients (n=8) 
5 patients (n=8) 
Тохгогіу 
The most imminent toxicity of this treatment appeared to be bone_marrow 
degression. In most patients the peripheral white cell count showed a nadir 
9 
below 1.0 χ 10 /liter. Bone marrow depression was more pronounced with the 
2 
regimen of 500 mg/m than with the lower dosage schemes. Restoration of the 
peripheral blood counts occurred about 2 weeks after the last injection (range 
10 to 30 days) without obvious relation with the dose. Patients attaining 
complete remission showed slightly earlier bone marrow recovery. 
9?5ï!r9:!!]Î§§ÎlDËl_tOi<içiti; is a well-known side-effect of ara-C. Nausea and 
vomiting happened in 10 patients, starting about 4 hours after injection and 
subsiding 2 to 10 hours later. Complaints were more pronounced in patients 
treated with 500 mg/m . During the treatment course these symptoms usually 
diminished. Weight loss of more than 5% of the body weight occurred in 3 
patients of whom 2 suffered from severe infection with high fever lasting 
more than 1 week. A severe gastro-intestinal syndrome as occuring during 
continuous infusions of high-dose ara-C [20] was not observed. 
2 
In patients treated with injections of 500 mg/m eye^toxicity occurred as 
133 
an unexpected side-effect. Pain and photofobia started after 5 to 7 injections 
and aggravated rapidly. Furthermore, patients suffered from tearing, blurred 
vision and conjunctival hyperemia. This syndrome, recently described for the 
first time [21], occurred in 5 out of the 8 patients treated for at least 5 
days. In 3 patients the complaints urged to cessation of therapy. The symptoms 
resolved completely, mostly within 2 days after ara-C administration was 
stopped. None of the patients had concomitant mucositis. In the tears neither 
ara-C not ara-U was detectable. 
The side-effects are summarized in table 2. 
DISCUSSION 
Treatment in patients with relapsed or refractory acute myeloid leukemia is 
usually very disappointing. With a great variety of chemotherapeutic agents in 
different combinations, complete remissions are achieved in only 5 to 30?» of 
the patients [1, 11, 22, 23, 24, 25, 26, 27, 28, 29]. Higher percentages of 
complete remission have been reported only in patients treated for first 
relapse [4, 30, 31, 32]. With the treatment scheme used in this study, 
complete remission is obtained in 30% of the patients after one treatment 
2 
course. The antileukemic efficacy of daily injections with 200 to 500 mg/m 
ara-C is also reflected in the disappearance rates of the peripheral blasts 
(Fig 1), which are comparable to those found by van Prooi jen [8] in previously 
untreated patients, using a twice daily scheme of 100 mg/m . 
The toxicity of injections with intermediate dose ara-C during 7 to 14 days 
is acceptable. Even in this group of patients with compromized progenitor cell 
pools, bone marrow toxicity is not more marked than with other induction 
schemes. In patients treated with an additional injection of an anthracycline 
derivative, bone marrow toxicity is not enhanced. The shorter duration of the 
aplastic period in patients achieving complete remission may be due to more 
effective tumor reduction or to a higher number of residual progenitor cells. 
Nausea and vomiting occur frequently some hours after ara-C injection. 
2 
Although complaints are more severe in patients treated with 500 mg/m , they 
usually do not urge to cessation of therapy. Gastro-intestinal toxicity seems 
not very impressive. Nevertheless, toxicity to the intestinal epithel i a may be 
severe [20] and should not be underestimated. 
In the past, eye-toxicity has not been reported as side-effect of systemic 
ara-C administration [33]. Recently it has been described for the first time 
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in 3 patients treated with short infusions of 3000 mg/m ara-C [21]. In the 
present study it appears to be a frequent and troublesome side-effect, occuring 
2 
in patients treated with injections of 500 mg/m only. The clinical picture 
resembles corneal toxicity seen after topical administration of ara-C [34]. 
The corneal lesions consist of epithelial opacities and microcysts [21, 34] 
probably due to inhibition of the DNA synthesis of the corneal epithelium. 
Local application of deoxycytidine may prevent these toxic effects [34]. 
It can be concluded that toxicity of ara-C therapy consisting of daily 
injections of 200 to 500 mg/m during 7 to 14 days is acceptable. This 
treatment scheme results in about 30% complete remissions in relapsed and 
refractory patients. This way of scheduling should be considered in treatment 
failures and for consolidation or reinforcement therapy in acute myeloid 
leukemia. 
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SUMMARY 
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The clinical effect of treatment with cytosine arabinoside (ara-C) in 
acute leukemia is the resultant of successive dynamic processes. Insight in 
these processes and their interrelationships may attribute to better under-
standing of individual variations in treatment results, in order to 
individualize and optimalize therapeutic schedules. 
In chapter 1 the present knowledge about clinical efficacy, metabolism, 
mode of action, and cytokinetic effects of ara-C is briefly reviewed. 
Mechanisms which have been reported to be responsible for ara-C resistance 
are mentioned. Based on this information, a dose-effect diagram of ara-C is 
designed. The studies described in the following chapters deal with different 
aspects, which may affect the response to ara-C therapy. 
In chapter ? a newly developed, sensitive method for the determination of 
ara-C and its inactive metabolite uracil arabinoside (ara-U) is described, 
using high pressure liquid chromatography. 
In chapter 3 a pharmacokinetic study on increasing dosages ara-C, 
administered either by constant rate infusion or by bolus injection, is 
reported. Rapidly metabolic inactivation of ara-C to ara-U hampers proper 
analysis of ara-C plasmaconcentration versus time curves, obtained after 
bolus injection. Methods to overcome this problem are discussed. The pharmaco-
kinetics of constant rate infusions is adequately described by first order 
? 
kinetics up to infusion rates of about 3000 mg/m /hr. However, when dosages 
of 500 mg/m or more are administered by bolus injection, saturation of the 
deaminating enzymes affects the pharmacokinetics of ara-C: plasma (and 
tissue) concentrations, found after distribution, appear to be higher than 
expected. 
In chapter 4 the concentrations of ara-C and ara-U, measured in cerebro-
2 
spinal fluid after intravenous bolus injections of 500 mg/m (n=10) and 1000 
2 
mg/m (n=12), are reported. Ara-C concentrations achieved within this 
compartment are cytotoxic and show a reduced elimination in comparison to 
plasma elimination, due to the absence of deaminating enzymes. It is concluded 
that ara-C has favourable properties for prophylaxis and treatment of 
meningeal involvement. 
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ín chai ver b studies are reported about the phosphorylation of ara-C to 
its active metabolite ara-C triphosphate (ara-CTP) and the subsequent 
inactivation by dephosphorylation, measured in leukemic bone marrow cells of 
61 patients with acute leukemia. The phosphorylation steps appear to be 
saturable half maximal rates are achieved at ara-C concentrations of about 
4 μΜ (range 1.1 to 16 μΜ). Administration of dosages producing concentrations 
above 10 μΜ will not lead to higher amounts of the active metabolite ara-CTP 
in the leukemic cells. The maximal rate of ara-CTP formation show marked 
variation, ranging from 18 to 190 pmol/10 cells in 30 minutes. In this 
respect lymphoblasts are as active as myeloblasts Leukemic cells of relapsed 
patients show even a higher phosphorylation activity, so that diminished 
clinical efficacy in this patient group can not be explained by impaired 
phosphorylation. 
Dephosphorylation of intracellular ara-CTP shows first-order kinetics 
with half-life times ranging from 55 to 210 minutes. Therefore, ara-CTP is 
retained longer in the target cells as suggested by the plasma elimination of 
ara-C. 
In chapter 6' the effect of ara-C on the DNA synthesis of leukemic bone 
marrow cells of 55 patients is described. The ara-C concentrations inhibiting 
3 
Η-thymidine incorporation in vitro for 90°», range from 0.06 to 8 μΜ. A 
50%-inhibition is achieved at ara-C concentrations which are about one decade 
lower. 
In patients with untreated acute myeloid leukemia high inhibition percentages 
correlate with higher phosphorylation activity of the cells. Inhibition of 
90% corresponds with 1.1 to 12.0 pmol ara-CTP/10 cells. This amount is slightly 
dependent on the percentage DNA-synthesizing cells (S-phase cells) in the 
sample. For this patient category high inhibition in vitro corresponds with 
better clinical response to remission induction therapy. 
Leukemic cells of patients with relapsed acute myeloid leukemia, are 
inhibited by ara-C as effectively as leukemic cells of untreated patients. 
However, no correlation between ara-CTP formation and effect on thymidine 
incorporation is observed in the relapsed patients. 
Lymphoblasts are inhibited at lower ara-C concentrations than myeloblasts. 
Inhibition of 90% is achieved in lymphoblasts with ara-C concentrations of 
0.02 to 0.2 μΜ, corresponding with 0 2 to 2.9 pmol ara-CTP/106 cells. 
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In chapter 7 the variation of the phosphorylating activity during the 
different phases of the cell cycle is described. Leukemic bone marrow cells 
of 5 patients with acute myeloid leukemia have been separated in fractions 
by means of counterflow elutriation. The fractions are enriched with cells 
of the various phases of the cell cycle (early- and late-G^-phase, S-phase 
and G2+M-phase). Phosphorylation of ara-C appears to be not restricted to the 
cells in S-phase. Especially cells in mid- and late-G.-phase are capable of 
phosphorylating ara-C in considerable amounts. As the dephosphorylation of 
ara-CTP is a relatively slow process, these cells still may retain cytotoxic 
amounts of ara-CTP when entering S-phase later on. Therefore, the number of 
cells killed by one injection ara-C, may exceed the number of cells in S-phase 
at the moment of injection. 
In chapter 8 a newly developed high pressure liquid chromatographic 
procedure is described in order to determine low intracellular amounts of 
ara-CTP. Using this method, ara-CTP concentrations, achieved in leukemic 
cells during ara-C treatment with conventional dosages ara-C, can be measured. 
Data obtained in 3 patients during constant rate infusions show a linear 
increase of the intracellular amount of ara-CTP during the infusion period. 
After a bolus injection ara-CTP increases only during the initial 30 minutes. 
Elimination of ara-CTP from the cells exhibits first-order kinetics with 
half-life times of 60 and 120 minutes. Measurement of phosphorylation and 
dephosphorylation in vitro seems to describe adequately the in vivo processes. 
In chapter о the results of cytokinetic measurements in 11 patients with 
acute myeloid leukemia after ara-C administration are reported. In order to 
determine the optimal time interval between subsequent ara-C injections, 
inhibition of the proliferative activity and subsequent restoration have been 
studied after bolus injections of 100, 360, and 1000 mg/m ara-C. Pretreatment 
values are regained about 24 hours after injection. No signs of recruitment 
are observed, but the cells may be partially synchronized. No differences are 
observed between the three dosages. The data indicate that intervals of 24 
hours may enlarge the efficacy of subsequent ara-C injections. 
In chapter 10 the therapeutic and toxic effects of daily treatment with 
2 
ara-C injections of 200 to 500 mg/m in 16 patients with relapsed or refractory 
acute myeloid leukemia are reported. Ara-C has been administered for 7 to 14 
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days. In 5 patients a complete remission has been obtained. Toxicity of this 
treatment is acceptable, although gastro-intestinal toxicity is more severe 
in the higher dosage group. As unexpected side-effect eye-toxicity is 
observed in 5 out of 8 patients, treated with more than 5 injections of 
2 
500 mg/m . This troublesome side-effect (ocular pain, photophobia and blurred 
vision) resolves completely within a few days after cessation of ara-C 
administration. 
The various processes studied, like pharmacokinetics, intracellular 
metabolism and cell kinetics, are closely connected. Together, they modulate 
the response to ara-C therapy in the individual patient. The relative 
importance of these factors with respect to the ultimate effect, can be 
tested in a simulation model, in which all the variables are comprised. 
The reliability of such a model should be controlled by in vivo measurements. 
Subsequently, the model can be used to improve treatment results by adaptation 
of the treatment scheme to the variables in individual patients. 
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Cytosine arabinoside (ara-C) is een krachtig cytostaticum dat vooral 
gebruikt wordt voor de behandeling van patiënten met een akute myeloide 
leukemie. De chemische struktuur toont grote gelijkenis met die van deoxy-
cytidine, een bouwsteen van het DNA. Door deze gelijkenis interfereert ara-C 
met de DNA synthese. Hierdoor treedt celdood op van de DNA synthetiserende 
cellen, de zogenaamde S-fase cellen. 
Behandeling met ara-C leidt helaas m et bij alle patiënten tot een 
effektieve eliminatie van leukemische cellen. Om enig inzicht te krijgen in 
de oorzaak van deze individuele verschillen, zijn een aantal variabelen die 
het uiteindelijke resultaat van de behandeling bepalen, nader onderzocht. 
Na toediening verdeelt ara-C zich snel over de diverse compartimenten van 
het lichaam. Tezelfdertijd wordt ara-C omgezet in een onwerkzame stof, uracil 
arabinoside (ara-U). Deze omzetting vindt vooral in de lever plaats. Ara-U 
wordt vervolgens uitgescheiden via de meren. 
Om het verloop van de ara-C en ara-U concentraties in het bloed te kunnen 
bestuderen, diende eerst een bepalingsmethode ontwikkeld te worden. In 
hoofаьLUÍ ? wordt een methode beschreven om met behulp van hoge-druk vloei-
stof-chromatografie lage concentraties ara-C en ara-U in plasma (en eventueel 
urine of hersenvocht) te kunnen meten. 
De detectiegrens voor ara-C is 0.008 uM, voor ara-U ongeveer 0.4 yM. 
Met deze methode werden ara-C en ara-U concentraties in plasma bepaald 
na intraveneuze toediening van ara-C. Zowel injekties als infusen werden 
vervolgd (}oofdsUt< />). 
Ara-C blijkt na intraveneuze toediening zeer snel afgebroken te worden tot 
ara-U (plasmaklaring 2 tot 8 l/min). De halfwaardetijden van ara-C zijn 
daardoor kort ( van 13 tot 33 min). Ara-U ontstaat derhalve zeer snel en 
wordt maar langzaam uitgescheiden (plasmaklaring 0.1 tot 0.8 l/min). De 
halfwaardetijden van ara-U variëren van 33 tot 330 minuten. 
Ook werd bekeken welk effekt dosis verhoging heeft op de plasmaconcen-
tratie. Bij toenemende doseringen stijgt de plasmaconcentratie van ara-C 
onevenredig veel. Dit is het gevolg van de verzadiging van het enzym dat 
ara-C afbreekt, het cytidine deaminase. Indien ara-C als infuus wordt toe-
gediend (tot 3000 mg/m /uur) treedt deze verzadiging m et op. 
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De meeste cytostatica dringen slechts matig door in het hersenvocht. 
Aangezien in het centrale zenuwstelsel leukemsche cellen aanwezig kunnen 
zijn, die bij onvoldoende behandeling zullen leiden tot een manifeste 
lokalisatie in het centrale zenuwstelsel, is het van belang te weten of er 
een effektieve concentratie bereikt wordt in dit compartiment. Derhalve 
werd de ara-C concentratie in het hersenvocht gemeten na intraveneuze 
injekties met 500 en 1000 mg/m ara-C [hoofdstuk 4). 
Vrij kort na de intraveneuze toediening van ara-C worden in het hersen-
vocht ara-C concentraties van ongeveer 5 uM bereikt. Deze concentraties 
hebben een duidelijk remmende werking op leukemische cellen. Twee uur na 
injektie blijkt de ara-C concentratie in het hersenvocht ongeveer 5 maal 
hoger te zijn dan de plasmaconcentratie op dat moment. Dit hangt samen met 
het feit dat het enzym cytidine deaminase m e t in het hersenweefsel vóór-
komt, zodat ara-C in het hersenvocht slechts langzaam wordt afgebroken. 
De halfwaardetijd van ara-C in het hersenvocht is daardoor langer dan die in 
het plasma ( ongeveer 100 min). 
Op grond van deze bevindingen verdient het aanbeveling om ara-C ook te 
gaan gebruiken bij de behandeling van akute lymfoblasten leukemie, aangezien 
deze vorm van leukemie vaak gekompliceerd wordt door een lokalisatie in het 
centrale zenuwstelsel. 
Om de cel-proliferatie te kunnen remmen, moet ara-C eerst omgezet worden 
in de cel tot ara-C trifosfaat (ara-CTP), aangezien alleen ara-CTP in staat 
is de DNA synthese te blokkeren. Bij de vorming van ara-CTP zijn meerdere 
enzymen betrokken. Het enzym dat de eerste fosforylerings-stap katalyseert, 
het deoxycytidine kinase, bepaalt de snelheid waarmee ara-CTP gevormd wordt. 
De vorming van ara-CTP werd in vitro gemeten in de leukemische cellen van 
69 patiënten (hoofdstuk 5). 
De vorming van ara-CTP raakt verzadigd bij ara-C concentraties boven 5 μΜ. 
Daarom zullen doseringen ara-C,welke leiden tot ara-C concentraties die hoger 
zijn, weinig zin hebben, aangezien zij slechts gepaard zullen gaan met een 
geringe toename van de snelheid waarmee ara-CTP in de leukemische cellen 
wordt gevormd. De maximale snelheid waarmee ara-CTP gevormd wordt in de 
leukemische cellen blijkt sterk uiteen te lopen (van 12 tot 125 pmol/10 cel­
len in 30 minuten). Er werd geen systematisch verschil gevonden tussen 
myeloblasten en lymfoblasten. 
Indien de leukemische cellen in staat zijn veel ara-CTP te vormen, lijkt 
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de patient gunstiger te reageren op ara-C behandeling. Dit geldt echter niet 
voor patiënten met een recidief die al eerder behandeld zijn met ara-C. Want 
hoewel bij deze patiënten de resultaten van ara-C behandeling veelal teleur-
stellend zijn, blijken de blasten wel degelijk veel ara-CTP te kunnen vormen. 
In vitro werd ook gemeten met welke snelheid het ara-CTP in de cel weer 
wordt afgebroken. Dit proces verloopt tamelijk traag: de halfwaardetijden 
variëren van 60 tot 210 minuten. Ara-CTP is kennelijk veel langer in de cellen 
aanwezig dan ara-C in het bloed. 
Het belangrijkste biochemische effekt van ara-C is het remmen van de DNA 
synthese. Bij 55 patiënten werd daarom het effekt van ara-C op de inbouw 
van radioaktief-gelabeld thymidine (een maat voor de DNA synthese) in de 
leukemische cellen in vitro gemeten (hoofdstuk 6 ) . 
Ook nu blijken er grote verschillen te bestaan tussen patiënten onderling. 
In tegenstelling tot de ara-CTP vorming, wordt er nu wel een duidelijk ver-
schil gevonden tussen myeloblasten en lymfoblasten: om de meeste Myeloblasten 
voor 90% te remmen is een ara-C concentratie van 1 μΜ nodig, terwijl lymfo­
blasten al bij een concentratie van 0.1 μΜ voor 90% geremd worden. 
Een sterker effekt in vitro van ara-C op de leukemische cellen van onbe­
handelde patiënten met akute myeloide leukemie gaat ook hier samen met 
betere behandelingsresultaten. Het effect van ara-C op DNA synthese blijkt 
enigszins te correleren met de mate waarin de cellen in staat zijn ara-CTP te 
vormen. 
De resultaten van deze bepalingen bij patiënten met recidi even bieden ander-
maal geen verklaring voor de slechtere behandelingsresultaten. 
Aangezien ara-C specifiek ingrijpt op de DNA synthese, zal het toxisch 
effekt alleen tot uiting komen in S-fase cellen. Dit hoeft echter niet te 
betekenen dat alleen S-fase cellen ara-CTP vormen. Uit de experimenten be-
schreven in hoofdstuk 7 blijkt dat ook niet-prolifererende cellen een aan-
zienlijke hoeveelheid ara-CTP vormen. Dit werd aangetoond door de ara-CTP 
vorming te meten in leukemische beenmergcellen, die door middel van tegen-
stroom-centrifugatie (elutriatie) gescheiden zijn in proliferende en niet-
prolifererende cellen. Vooral cellen die op kortere termijn toe zijn aan de 
S-fase blijken al veel ara-CTP te vormen. Aangezien ara-CTP vrij lang in de 
cel aanwezig blijft,is het zeer goed mogelijk dat deze cellen nog voldoende 
ara-CTP bevatten als de DNA synthese gaat beginnen, om celdood te induceren. 
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Het aantal cellen dat niet in S-fase is, maar dat wel ara-CTP vormt, kan van 
grote betekenis zijn voor het aantal cellen dat per ara-C injektie geëlimi-
neerd wordt. 
Tot voor kort kon de hoeveelheid ara-CTP in de cellen alleen bepaald worden 
met behulp van radioaktief-gelabeld ara-C, zodat metingen van de ara-CTP 
vorming in vivo onmogelijk waren. Om ook niet-radioaktief ara-CTP in leuke-
mische cellen te kunnen meten, werd een bepalingsmethode ontwikkeld met 
behulp van hoge-druk vloeistof-chromatografie [koofasink h). 
Met deze methode kunnen zeer kleine hoeveelheden ara-CTP bepaald worden: 
2 pmol/10 cellen is al aantoonbaar. 
De eerste meetresultaten bij patiënten tijdens ara-C behandeling wijzen 
erop dat de in vitro gemeten ara-CTP vorming en afbraak goede overeenkomst 
vertoont met de resultaten van in vivo metingen. 
Indien alle S-fase cellen door een ara-C injektie geëlimineerd zijn, zal 
het enige tijd duren voordat er een nieuwe lichting cellen in S-fase is. 
Wanneer de volgende ara-C injektie te kort na de eerste gegeven wordt, zal 
deze slechts weinig effekt sorteren. Om te bepalen welk tijdsinterval tussen 
opeenvolgende injekties optimaal is, werd bij 11 patiënten op verschillende 
tijdstippen na een ara-C injektie het aantal en de aktiviteit van de S-fase 
cellen gemeten door middel van autoradiografie, DNA-flowcytometrie en 
thymidine inbouw [hoofdstuk 9). 
Zeven uur na injektie blijkt de aktiviteit van de ÜNA synthese nog sterk 
verlaagd te zijn. Na 24 uur zijn de waarden vergelijkbaar met die van voor 
de ara-C toediening. Een reaktieve toename van het aantal S-fase cellen, 
zoals wel bij ratten-leukemie is waargenomen, treedt niet op. Wel lijken de 
nieuwe S-fase cellen enigszins synchroon door deze fase heen te gaan. 
Op grond van deze waarnemingen lijken ara-C injekties om de 24 uur een 
hoger rendement op te leveren dan injekties om de 12 uur, zoals nu gebrui-
kelijk is. 
In hoofdstuk 10 worden de resultaten en de bijwerkingen beschreven van 
2 
behandeling met middelhoge doseringen ara-C (200 tot 500 mg/m ara-C, bolus 
injekties om de 24 uur gedurende 7 tot 14 dagen) bij patiënten met een 
recidief acute leukeirie en bij patiënten die niet gereageerd hebben op de 
gebruikelijke behandeling. 
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Van de 14 evalueerbare patiënten bereikten er 5 een komplete remissie. 
De beenmergaplasie, die onvermijdelijk is bij de leukemie behandeling, 
duurt tot ongeveer 14 dagen na de kuur. De ernst van de optredende misselijk-
heid en het braken neemt toe bij hogere doseringen. Bij patiënten die be-
2 handeld werden met doses van 500 mg/m traden frekwent klachten van de ogen 
op. Een paar maal waren deze zelfs zo hevig dat ara-C toediening onderbroken 
moest worden. Daarna verdwenen de klachten weer snel. Deze bijwerking is 
nooit gezien bij lagere doseringen en is slechts een enkele keer eerder 
beschreven. 
Zoals uit de resultaten van de verrichtte studies blijkt, vertonen de 
faktoren die voor het uiteindelijke effekt van een ara-C behandeling be-
langrijk zijn, grote individuele verschillen. Het is dan ook niet verwonder-
lijk dat patiënten zo verschillend reageren op een uniform terapieschema. 
In de toekomst zal er naar gestreefd dienen te worden het behandelingsschema 
van ara-C aan te passen aan de (gemeten) parameters van de individuele 
patient. 
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